for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Oxford University Press   (Total: 406 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 406 Journals sorted alphabetically
ACS Symposium Series     Full-text available via subscription   (Followers: 1, SJR: 0.189, CiteScore: 0)
Acta Biochimica et Biophysica Sinica     Hybrid Journal   (Followers: 5, SJR: 0.79, CiteScore: 2)
Adaptation     Hybrid Journal   (Followers: 9, SJR: 0.143, CiteScore: 0)
Advances in Nutrition     Hybrid Journal   (Followers: 54, SJR: 2.196, CiteScore: 5)
Aesthetic Surgery J.     Hybrid Journal   (Followers: 6, SJR: 1.434, CiteScore: 1)
Aesthetic Surgery J. Open Forum     Open Access  
African Affairs     Hybrid Journal   (Followers: 66, SJR: 1.869, CiteScore: 2)
Age and Ageing     Hybrid Journal   (Followers: 90, SJR: 1.989, CiteScore: 4)
Alcohol and Alcoholism     Hybrid Journal   (Followers: 18, SJR: 1.376, CiteScore: 3)
American Entomologist     Full-text available via subscription   (Followers: 8)
American Historical Review     Hybrid Journal   (Followers: 179, SJR: 0.467, CiteScore: 1)
American J. of Agricultural Economics     Hybrid Journal   (Followers: 44, SJR: 2.113, CiteScore: 3)
American J. of Clinical Nutrition     Hybrid Journal   (Followers: 187, SJR: 3.438, CiteScore: 6)
American J. of Epidemiology     Hybrid Journal   (Followers: 195, SJR: 2.713, CiteScore: 3)
American J. of Health-System Pharmacy     Full-text available via subscription   (Followers: 55, SJR: 0.595, CiteScore: 1)
American J. of Hypertension     Hybrid Journal   (Followers: 26, SJR: 1.322, CiteScore: 3)
American J. of Jurisprudence     Hybrid Journal   (Followers: 19, SJR: 0.281, CiteScore: 1)
American J. of Legal History     Full-text available via subscription   (Followers: 9, SJR: 0.116, CiteScore: 0)
American Law and Economics Review     Hybrid Journal   (Followers: 28, SJR: 1.053, CiteScore: 1)
American Literary History     Hybrid Journal   (Followers: 17, SJR: 0.391, CiteScore: 0)
Analysis     Hybrid Journal   (Followers: 23, SJR: 1.038, CiteScore: 1)
Animal Frontiers     Hybrid Journal   (Followers: 1)
Annals of Behavioral Medicine     Hybrid Journal   (Followers: 16, SJR: 1.423, CiteScore: 3)
Annals of Botany     Hybrid Journal   (Followers: 38, SJR: 1.721, CiteScore: 4)
Annals of Oncology     Hybrid Journal   (Followers: 55, SJR: 5.599, CiteScore: 9)
Annals of the Entomological Society of America     Full-text available via subscription   (Followers: 11, SJR: 0.722, CiteScore: 1)
Annals of Work Exposures and Health     Hybrid Journal   (Followers: 34, SJR: 0.728, CiteScore: 2)
Antibody Therapeutics     Open Access  
AoB Plants     Open Access   (Followers: 4, SJR: 1.28, CiteScore: 3)
Applied Economic Perspectives and Policy     Hybrid Journal   (Followers: 17, SJR: 0.858, CiteScore: 2)
Applied Linguistics     Hybrid Journal   (Followers: 60, SJR: 2.987, CiteScore: 3)
Applied Mathematics Research eXpress     Hybrid Journal   (Followers: 1, SJR: 1.241, CiteScore: 1)
Arbitration Intl.     Full-text available via subscription   (Followers: 21)
Arbitration Law Reports and Review     Hybrid Journal   (Followers: 14)
Archives of Clinical Neuropsychology     Hybrid Journal   (Followers: 30, SJR: 0.731, CiteScore: 2)
Aristotelian Society Supplementary Volume     Hybrid Journal   (Followers: 3)
Arthropod Management Tests     Hybrid Journal   (Followers: 2)
Astronomy & Geophysics     Hybrid Journal   (Followers: 44, SJR: 0.146, CiteScore: 0)
Behavioral Ecology     Hybrid Journal   (Followers: 53, SJR: 1.871, CiteScore: 3)
Bioinformatics     Hybrid Journal   (Followers: 347, SJR: 6.14, CiteScore: 8)
Biology Methods and Protocols     Hybrid Journal  
Biology of Reproduction     Full-text available via subscription   (Followers: 10, SJR: 1.446, CiteScore: 3)
Biometrika     Hybrid Journal   (Followers: 20, SJR: 3.485, CiteScore: 2)
BioScience     Hybrid Journal   (Followers: 29, SJR: 2.754, CiteScore: 4)
Bioscience Horizons : The National Undergraduate Research J.     Open Access   (Followers: 2, SJR: 0.146, CiteScore: 0)
Biostatistics     Hybrid Journal   (Followers: 17, SJR: 1.553, CiteScore: 2)
BJA : British J. of Anaesthesia     Hybrid Journal   (Followers: 188, SJR: 2.115, CiteScore: 3)
BJA Education     Hybrid Journal   (Followers: 66)
Brain     Hybrid Journal   (Followers: 70, SJR: 5.858, CiteScore: 7)
Briefings in Bioinformatics     Hybrid Journal   (Followers: 49, SJR: 2.505, CiteScore: 5)
Briefings in Functional Genomics     Hybrid Journal   (Followers: 3, SJR: 2.15, CiteScore: 3)
British J. for the Philosophy of Science     Hybrid Journal   (Followers: 38, SJR: 2.161, CiteScore: 2)
British J. of Aesthetics     Hybrid Journal   (Followers: 25, SJR: 0.508, CiteScore: 1)
British J. of Criminology     Hybrid Journal   (Followers: 603, SJR: 1.828, CiteScore: 3)
British J. of Social Work     Hybrid Journal   (Followers: 86, SJR: 1.019, CiteScore: 2)
British Medical Bulletin     Hybrid Journal   (Followers: 6, SJR: 1.355, CiteScore: 3)
British Yearbook of Intl. Law     Hybrid Journal   (Followers: 35)
Bulletin of the London Mathematical Society     Hybrid Journal   (Followers: 4, SJR: 1.376, CiteScore: 1)
Cambridge J. of Economics     Hybrid Journal   (Followers: 71, SJR: 0.764, CiteScore: 2)
Cambridge J. of Regions, Economy and Society     Hybrid Journal   (Followers: 12, SJR: 2.438, CiteScore: 4)
Cambridge Quarterly     Hybrid Journal   (Followers: 10, SJR: 0.104, CiteScore: 0)
Capital Markets Law J.     Hybrid Journal   (Followers: 2, SJR: 0.222, CiteScore: 0)
Carcinogenesis     Hybrid Journal   (Followers: 2, SJR: 2.135, CiteScore: 5)
Cardiovascular Research     Hybrid Journal   (Followers: 14, SJR: 3.002, CiteScore: 5)
Cerebral Cortex     Hybrid Journal   (Followers: 52, SJR: 3.892, CiteScore: 6)
CESifo Economic Studies     Hybrid Journal   (Followers: 23, SJR: 0.483, CiteScore: 1)
Chemical Senses     Hybrid Journal   (Followers: 1, SJR: 1.42, CiteScore: 3)
Children and Schools     Hybrid Journal   (Followers: 6, SJR: 0.246, CiteScore: 0)
Chinese J. of Comparative Law     Hybrid Journal   (Followers: 5, SJR: 0.412, CiteScore: 0)
Chinese J. of Intl. Law     Hybrid Journal   (Followers: 23, SJR: 0.329, CiteScore: 0)
Chinese J. of Intl. Politics     Hybrid Journal   (Followers: 10, SJR: 1.392, CiteScore: 2)
Christian Bioethics: Non-Ecumenical Studies in Medical Morality     Hybrid Journal   (Followers: 10, SJR: 0.183, CiteScore: 0)
Classical Receptions J.     Hybrid Journal   (Followers: 27, SJR: 0.123, CiteScore: 0)
Clean Energy     Open Access   (Followers: 1)
Clinical Infectious Diseases     Hybrid Journal   (Followers: 70, SJR: 5.051, CiteScore: 5)
Communication Theory     Hybrid Journal   (Followers: 25, SJR: 2.424, CiteScore: 3)
Communication, Culture & Critique     Hybrid Journal   (Followers: 28, SJR: 0.222, CiteScore: 1)
Community Development J.     Hybrid Journal   (Followers: 27, SJR: 0.268, CiteScore: 1)
Computer J.     Hybrid Journal   (Followers: 9, SJR: 0.319, CiteScore: 1)
Conservation Physiology     Open Access   (Followers: 3, SJR: 1.818, CiteScore: 3)
Contemporary Women's Writing     Hybrid Journal   (Followers: 9, SJR: 0.121, CiteScore: 0)
Contributions to Political Economy     Hybrid Journal   (Followers: 6, SJR: 0.906, CiteScore: 1)
Critical Values     Full-text available via subscription  
Current Developments in Nutrition     Open Access   (Followers: 3)
Current Legal Problems     Hybrid Journal   (Followers: 29)
Current Zoology     Full-text available via subscription   (Followers: 3, SJR: 1.164, CiteScore: 2)
Database : The J. of Biological Databases and Curation     Open Access   (Followers: 9, SJR: 1.791, CiteScore: 3)
Digital Scholarship in the Humanities     Hybrid Journal   (Followers: 14, SJR: 0.259, CiteScore: 1)
Diplomatic History     Hybrid Journal   (Followers: 21, SJR: 0.45, CiteScore: 1)
DNA Research     Open Access   (Followers: 5, SJR: 2.866, CiteScore: 6)
Dynamics and Statistics of the Climate System     Open Access   (Followers: 4)
Early Music     Hybrid Journal   (Followers: 17, SJR: 0.139, CiteScore: 0)
Econometrics J.     Hybrid Journal   (Followers: 32, SJR: 2.926, CiteScore: 1)
Economic J.     Hybrid Journal   (Followers: 116, SJR: 5.161, CiteScore: 3)
Economic Policy     Hybrid Journal   (Followers: 48, SJR: 3.584, CiteScore: 3)
ELT J.     Hybrid Journal   (Followers: 24, SJR: 0.942, CiteScore: 1)
English Historical Review     Hybrid Journal   (Followers: 56, SJR: 0.612, CiteScore: 1)
English: J. of the English Association     Hybrid Journal   (Followers: 18, SJR: 0.1, CiteScore: 0)
Environmental Entomology     Full-text available via subscription   (Followers: 11, SJR: 0.818, CiteScore: 2)
Environmental Epigenetics     Open Access   (Followers: 2)
Environmental History     Hybrid Journal   (Followers: 26, SJR: 0.408, CiteScore: 1)
EP-Europace     Hybrid Journal   (Followers: 3, SJR: 2.748, CiteScore: 4)
Epidemiologic Reviews     Hybrid Journal   (Followers: 9, SJR: 4.505, CiteScore: 8)
ESHRE Monographs     Hybrid Journal  
Essays in Criticism     Hybrid Journal   (Followers: 20, SJR: 0.113, CiteScore: 0)
European Heart J.     Hybrid Journal   (Followers: 66, SJR: 9.315, CiteScore: 9)
European Heart J. - Cardiovascular Imaging     Hybrid Journal   (Followers: 10, SJR: 3.625, CiteScore: 3)
European Heart J. - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 2)
European Heart J. - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart J. : Case Reports     Open Access  
European Heart J. Supplements     Hybrid Journal   (Followers: 8, SJR: 0.223, CiteScore: 0)
European J. of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9, SJR: 1.681, CiteScore: 2)
European J. of Intl. Law     Hybrid Journal   (Followers: 205, SJR: 0.694, CiteScore: 1)
European J. of Orthodontics     Hybrid Journal   (Followers: 5, SJR: 1.279, CiteScore: 2)
European J. of Public Health     Hybrid Journal   (Followers: 19, SJR: 1.36, CiteScore: 2)
European Review of Agricultural Economics     Hybrid Journal   (Followers: 10, SJR: 1.172, CiteScore: 2)
European Review of Economic History     Hybrid Journal   (Followers: 30, SJR: 0.702, CiteScore: 1)
European Sociological Review     Hybrid Journal   (Followers: 43, SJR: 2.728, CiteScore: 3)
Evolution, Medicine, and Public Health     Open Access   (Followers: 12)
Family Practice     Hybrid Journal   (Followers: 15, SJR: 1.018, CiteScore: 2)
Fems Microbiology Ecology     Hybrid Journal   (Followers: 16, SJR: 1.492, CiteScore: 4)
Fems Microbiology Letters     Hybrid Journal   (Followers: 28, SJR: 0.79, CiteScore: 2)
Fems Microbiology Reviews     Hybrid Journal   (Followers: 33, SJR: 7.063, CiteScore: 13)
Fems Yeast Research     Hybrid Journal   (Followers: 14, SJR: 1.308, CiteScore: 3)
Food Quality and Safety     Open Access   (Followers: 1)
Foreign Policy Analysis     Hybrid Journal   (Followers: 24, SJR: 1.425, CiteScore: 1)
Forest Science     Hybrid Journal   (Followers: 8, SJR: 0.89, CiteScore: 2)
Forestry: An Intl. J. of Forest Research     Hybrid Journal   (Followers: 16, SJR: 1.133, CiteScore: 3)
Forum for Modern Language Studies     Hybrid Journal   (Followers: 6, SJR: 0.104, CiteScore: 0)
French History     Hybrid Journal   (Followers: 34, SJR: 0.118, CiteScore: 0)
French Studies     Hybrid Journal   (Followers: 21, SJR: 0.148, CiteScore: 0)
French Studies Bulletin     Hybrid Journal   (Followers: 10, SJR: 0.152, CiteScore: 0)
Gastroenterology Report     Open Access   (Followers: 3)
Genome Biology and Evolution     Open Access   (Followers: 16, SJR: 2.578, CiteScore: 4)
Geophysical J. Intl.     Hybrid Journal   (Followers: 39, SJR: 1.506, CiteScore: 3)
German History     Hybrid Journal   (Followers: 23, SJR: 0.161, CiteScore: 0)
GigaScience     Open Access   (Followers: 6, SJR: 5.022, CiteScore: 7)
Global Summitry     Hybrid Journal   (Followers: 1)
Glycobiology     Hybrid Journal   (Followers: 13, SJR: 1.493, CiteScore: 3)
Health and Social Work     Hybrid Journal   (Followers: 57, SJR: 0.388, CiteScore: 1)
Health Education Research     Hybrid Journal   (Followers: 15, SJR: 0.854, CiteScore: 2)
Health Policy and Planning     Hybrid Journal   (Followers: 24, SJR: 1.512, CiteScore: 2)
Health Promotion Intl.     Hybrid Journal   (Followers: 22, SJR: 0.812, CiteScore: 2)
History Workshop J.     Hybrid Journal   (Followers: 33, SJR: 1.278, CiteScore: 1)
Holocaust and Genocide Studies     Hybrid Journal   (Followers: 28, SJR: 0.105, CiteScore: 0)
Human Communication Research     Hybrid Journal   (Followers: 15, SJR: 2.146, CiteScore: 3)
Human Molecular Genetics     Hybrid Journal   (Followers: 9, SJR: 3.555, CiteScore: 5)
Human Reproduction     Hybrid Journal   (Followers: 75, SJR: 2.643, CiteScore: 5)
Human Reproduction Open     Open Access   (Followers: 1)
Human Reproduction Update     Hybrid Journal   (Followers: 21, SJR: 5.317, CiteScore: 10)
Human Rights Law Review     Hybrid Journal   (Followers: 64, SJR: 0.756, CiteScore: 1)
ICES J. of Marine Science: J. du Conseil     Hybrid Journal   (Followers: 58, SJR: 1.591, CiteScore: 3)
ICSID Review : Foreign Investment Law J.     Hybrid Journal   (Followers: 11)
ILAR J.     Hybrid Journal   (Followers: 3, SJR: 1.732, CiteScore: 4)
IMA J. of Applied Mathematics     Hybrid Journal   (SJR: 0.679, CiteScore: 1)
IMA J. of Management Mathematics     Hybrid Journal   (SJR: 0.538, CiteScore: 1)
IMA J. of Mathematical Control and Information     Hybrid Journal   (Followers: 2, SJR: 0.496, CiteScore: 1)
IMA J. of Numerical Analysis - advance access     Hybrid Journal   (SJR: 1.987, CiteScore: 2)
Industrial and Corporate Change     Hybrid Journal   (Followers: 10, SJR: 1.792, CiteScore: 2)
Industrial Law J.     Hybrid Journal   (Followers: 41, SJR: 0.249, CiteScore: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 47, SJR: 2.511, CiteScore: 4)
Information and Inference     Free  
Innovation in Aging     Open Access  
Integrative and Comparative Biology     Hybrid Journal   (Followers: 9, SJR: 1.319, CiteScore: 2)
Integrative Biology     Full-text available via subscription   (Followers: 6, SJR: 1.36, CiteScore: 3)
Integrative Organismal Biology     Open Access  
Interacting with Computers     Hybrid Journal   (Followers: 11, SJR: 0.292, CiteScore: 1)
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7, SJR: 0.762, CiteScore: 1)
Intl. Affairs     Hybrid Journal   (Followers: 68, SJR: 1.505, CiteScore: 3)
Intl. Data Privacy Law     Hybrid Journal   (Followers: 27)
Intl. Health     Hybrid Journal   (Followers: 6, SJR: 0.851, CiteScore: 2)
Intl. Immunology     Hybrid Journal   (Followers: 3, SJR: 2.167, CiteScore: 4)
Intl. J. for Quality in Health Care     Hybrid Journal   (Followers: 36, SJR: 1.348, CiteScore: 2)
Intl. J. of Constitutional Law     Hybrid Journal   (Followers: 65, SJR: 0.601, CiteScore: 1)
Intl. J. of Epidemiology     Hybrid Journal   (Followers: 260, SJR: 3.969, CiteScore: 5)
Intl. J. of Law and Information Technology     Hybrid Journal   (Followers: 5, SJR: 0.202, CiteScore: 1)
Intl. J. of Law, Policy and the Family     Hybrid Journal   (Followers: 28, SJR: 0.223, CiteScore: 1)
Intl. J. of Lexicography     Hybrid Journal   (Followers: 10, SJR: 0.285, CiteScore: 1)
Intl. J. of Low-Carbon Technologies     Open Access   (Followers: 1, SJR: 0.403, CiteScore: 1)
Intl. J. of Neuropsychopharmacology     Open Access   (Followers: 3, SJR: 1.808, CiteScore: 4)
Intl. J. of Public Opinion Research     Hybrid Journal   (Followers: 11, SJR: 1.545, CiteScore: 1)
Intl. J. of Refugee Law     Hybrid Journal   (Followers: 39, SJR: 0.389, CiteScore: 1)
Intl. J. of Transitional Justice     Hybrid Journal   (Followers: 11, SJR: 0.724, CiteScore: 2)
Intl. Mathematics Research Notices     Hybrid Journal   (Followers: 1, SJR: 2.168, CiteScore: 1)
Intl. Political Sociology     Hybrid Journal   (Followers: 40, SJR: 1.465, CiteScore: 3)
Intl. Relations of the Asia-Pacific     Hybrid Journal   (Followers: 24, SJR: 0.401, CiteScore: 1)
Intl. Studies Perspectives     Hybrid Journal   (Followers: 9, SJR: 0.983, CiteScore: 1)
Intl. Studies Quarterly     Hybrid Journal   (Followers: 50, SJR: 2.581, CiteScore: 2)
Intl. Studies Review     Hybrid Journal   (Followers: 25, SJR: 1.201, CiteScore: 1)
ISLE: Interdisciplinary Studies in Literature and Environment     Hybrid Journal   (Followers: 2, SJR: 0.15, CiteScore: 0)
ITNOW     Hybrid Journal   (Followers: 1, SJR: 0.103, CiteScore: 0)
J. of African Economies     Hybrid Journal   (Followers: 17, SJR: 0.533, CiteScore: 1)
J. of American History     Hybrid Journal   (Followers: 46, SJR: 0.297, CiteScore: 1)
J. of Analytical Toxicology     Hybrid Journal   (Followers: 14, SJR: 1.065, CiteScore: 2)
J. of Antimicrobial Chemotherapy     Hybrid Journal   (Followers: 15, SJR: 2.419, CiteScore: 4)
J. of Antitrust Enforcement     Hybrid Journal   (Followers: 1)
J. of Applied Poultry Research     Hybrid Journal   (Followers: 5, SJR: 0.585, CiteScore: 1)
J. of Biochemistry     Hybrid Journal   (Followers: 41, SJR: 1.226, CiteScore: 2)
J. of Breast Imaging     Full-text available via subscription   (Followers: 1)
J. of Burn Care & Research     Hybrid Journal   (Followers: 11, SJR: 0.768, CiteScore: 2)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Annals of Oncology
Journal Prestige (SJR): 5.599
Citation Impact (citeScore): 9
Number of Followers: 55  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0923-7534 - ISSN (Online) 1569-8041
Published by Oxford University Press Homepage  [406 journals]
  • 92OValidating the CTS5 algorithm with the IDEAL study cohort
    • Authors: Noordhoek I; Blok E, Meershoek-Klein Kranenbarg E, et al.
      Abstract: Background: Half of the distant recurrences (DR) occur after the first five years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) intends to predict DR after 5 years of endocrine therapy (ET). This study uses the IDEAL study cohort, consisting of patients disease free after 5 years of standard adjuvant ET and randomized between 2.5 or 5 years of extended therapy with letrozole, to validate the CTS5 as a prognostic tool for late DR and, if it is validated, to examine it as a predictive tool for choosing between 2.5 years or 5 years of extended ET.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 91OCirculating tumor DNA and disease recurrence in early stage breast
           cancer: From a case-control study to a prospective longitudinal trial
    • Authors: Di Cosimo S; Appierto V, Ortolan E, et al.
      Abstract: Background: Biomarker/s able to detect minimal residual disease (MRD) after breast cancer (BC) surgery are needed to aid optimal systemic therapy. We aimed at investigating the feasibility of using circulating tumor DNA (ctDNA) to early detect MRD in plasma samples collected during the follow-up of patients (pts) with early BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 90OThe role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive
           (HER2+) early breast cancer (BC) patients (pts) before and after the
           introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial
    • Authors: Lambertini M; Bruzzone M, Poggio F, et al.
      Abstract: Background: DD adjuvant CT is standard of care in high-risk early BC pts. However, the role of DD CT in HER2+ BC pts remains uncertain, particularly when T is administered. In this exploratory analysis of the GIM2 trial (Del Mastro et al, Lancet 2015), we investigated the efficacy of DD CT in the subgroup of HER2+ BC pts with or without subsequent exposure to T.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 89OImpact of delayed adjuvant chemotherapy: The Royal Marsden Hospital
           (RMH) experience
    • Authors: Okines A; Kipps E, Irfan T, et al.
      Abstract: Background: The optimal time to deliver adjuvant chemotherapy has not been defined, although benefit for early chemotherapy (<20 days of surgery) was previously reported in pre-menopausal women with oestrogen-receptor (ER) negative cancers. More recently, a SEER database study demonstrated that overall survival declined with delays of ≥ 60 days.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 136PDecisions for immediate breast reconstruction: Do surgeons make
           sensible choices'
    • Authors: Zaidi M; Rezacova M, Mansfield L, et al.
      Abstract: Background: Current UK national guidelines recommend reconstruction discussion for all women undergoing mastectomy for breast cancer. The decision for immediate reconstruction lies with the surgeon, based on patient’s choice, comorbidities and expected post operative adjuvant treatments especially radiotherapy which may affect reconstruction outcome. The aim of our study was to review surgeons’ decisions for immediate breast reconstruction and their accuracy of prediction for post mastectomy radiotherapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 158P_PRIntermittent versus continuous chemotherapy beyond first-line for
           patients with HER2-negative advanced breast cancer (BOOG 2010-02)
    • Authors: Erdkamp F; Claessens A, Lopez-Yurda M, et al.
      Abstract: Background: This study investigates efficacy and safety of intermittent versus continuous scheduling of chemotherapy over two treatment lines for patients within the Stop & Go trial.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 88OValidation of the American Joint Committee on Cancer new prognostic
           stage groups for HER2-positive breast cancer patients treated with
           adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
    • Authors: Dieci M; Bisagni G, Brandes A, et al.
      Abstract: Background: The American Joint Committee on Cancer (AJCC) 8th edition staging system introduced prognostic stage groups based on anatomic stage combined with biologic factors. We aimed to validate the AJCC prognostic classification in a large cohort of patients with HER2-positive breast cancer enrolled in the prospective ShortHER trial.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 202P_PRAdherence to dietary guidelines (DG) and body weight change (BWC)
           in early-stage breast cancer (EBC): A prospective trial in patients
           submitted to nutrition evidence-based educational intervention
    • Authors: Carbognin L; Trestini I, Sperduti I, et al.
      Abstract: Background: Despite weight gain and overweight have been related to an increased risk of recurrence and mortality in patients with EBC, the adherence to nutritional intervention is not entirely explored. Therefore, the aims of this trial were to evaluate the adherence to DG and the effectiveness of nutritional intervention in terms of BWC in patients with EBC undergoing treatment.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 157PDifferences between breast cancer subtypes in developing metastatic
           disease
    • Authors: Wildiers H; van Mechelen M, van Herck A, et al.
      Abstract: Background: This large study aims to explore in depth the impact of breast cancer (BC) subtype on metastatic behavior and long term outcome.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 135PMulti-gene panel testing at the hereditary breast and ovarian cancer
           (HBOC) unit of the Hospital Clinic of Barcelona
    • Authors: Adamo B; Moreno L, Gaba L, et al.
      Abstract: Background: The variety and clinical characteristics of BRCA1/2 and non-BRCA1/2 mutations in women with a suspicion of HBOC before the implementation of multi-gene panels in our referral population was unknown.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 22PESR1 mutations are similarly prevalent in newly metastatic and
           loco-regional recurrence of endocrine-treated breast cancer patients and
           carry worse prognosis
    • Authors: Nili Gal Yam E; Zundelevich A, Dadiani M, et al.
      Abstract: Background: Mutations in the ESR1 gene that evolve under endocrine treatment are associated with resistance to therapy and with worse prognosis of HR positive metastatic breast cancer patients. Here we aimed to study the incidence and clinical implication of these mutations in local recurrence events and newly diagnosed metastases.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.021
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 87OImpact of older age on the locoregional and distant breast cancer
           recurrence risk: A large population-based study
    • Authors: de Boer A; van der Hulst H, van der Plas-Krijgsman W, et al.
      Abstract: Background: Although previous studies have suggested a higher risk of breast cancer recurrence with increasing age, older patients with early stage breast cancer generally receive less extensive treatment. The aim of this study was to evaluate the impact of older age on risk of locoregional and distant recurrence among patients aged 70 years or older in a large population based cohort.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 201PPreventive bilateral mastectomy (PBS) in BRCA mutation carriers with
           ovarian cancer: Is it justified'
    • Authors: Safra T; Waissengrin B, Gerber D, et al.
      Abstract: Background: To determine the incidence of breast cancer (BC) in BRCA mutation carriers (BRCA+) after ovarian cancer (OC) diagnosis, and to re-evaluate BC surveillance in BRCA+ with OC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 134PThe negative pressure therapy with PICO as a prevention of surgical
           site infection in high risk patients undergoing breast surgery
    • Authors: Fogacci T; Cattin F, Samorani D.
      Abstract: Background: The negative pressure therapy (NPWT) is usually used to treat difficult and chronic wounds. Among NPWT devices, some of them, like PICO, have a proven utility as a prophylaxis against surgical wound complications in high risk patients. PICO is a fixed intensity instrument, working with a continuous -80mmHg pressure over the wound.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 156PPalbociclib plus fulvestrant as first-line therapy for patients with
           locally advanced, inoperable or metastatic HR+/HER2- breast cancer in
           Germany: Interim results of the INGE-B phase II study
    • Authors: Welt A; Welslau M, Lüftner D, et al.
      Abstract: Background: In the PALOMA-3 trial, palbociclib plus fulvestrant demonstrated a clinically meaningful improvement in overall survival compared with fulvestrant plus placebo in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer who had relapsed or progressed on prior endocrine therapy (Turner NC et al., NEJM 2018). Detailed analyses for first-line (1L) and later-line (2L+) therapy are still limited.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 21PCharacteristics of circulating tumor DNA (ctDNA) in patients with
           ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on
           different lines of endocrine treatment
    • Authors: Bos M; Kruger D, Jansen M, et al.
      Abstract: Background: ctDNA is emerging as a non-invasive disease-monitoring biomarker alternative to a tissue biopsy. In this study, we characterized ctDNA from patients with ER+, HER2- MBC 1) starting first-line non-steroidal aromatase inhibitors (NSAIs) and 2) refractory to treatment with NSAI.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.020
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • Drug Index
    • Abstract: [Fam-]trastuzumab deruxtecan (DS-8201a): 194TiP, 197TiP
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz148
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 114PThe incidence of metastases detected on a staging CT scan prior to
           neoadjuvant chemotherapy in early stage breast cancer
    • Authors: Broadbent R; Ralston S, Armstrong A, et al.
      Abstract: Background: The role of neoadjuvant chemotherapy (NACT) in the treatment of early stage breast cancer is well established. Guidelines differ in their recommendation for staging work-up prior to NACT. Our institutional guidelines recommend CT thorax abdomen and pelvis scan for all such patients and we sought to evaluate the rate of metastatic disease by breast cancer stage.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 200PNon-invasive and low-cost technique for early detection of clinically
           relevant breast lesions using a handheld point-of-care medical device
           (iBreast): Prospective three-arm triple-blinded comparative study for
           breast cancer screening in low resource setting countries
    • Authors: Kr A.
      Abstract: Background: iBreast is an unique portable handheld non-invasive medical device which is developed in India to screen patients in rural and suburban areas. It employs a lead zirconate titanate piezoelectric cantilever sensor and can accurately detect abnormal areas by comparing the degree of deflection. Our tripled blinded study compares it with Clinical Breast Examination and Mammography and breast ultrasound.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 85TiPPhase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for
           characterization of HER2 presence in brain metastases of breast cancer
           patients
    • Authors: Keyaerts M; Xavier C, Everaert H, et al.
      Abstract: Background: Brain metastases form a challenge in breast cancer patients, especially in HER2+ patients whose peripheral metastases can often be controlled using standard-of-care HER2 regimens, but with relapse or progression in the brain. This determines survival for such patients. Penetration in brain lesions as well as the therapeutic outcome can be hampered due to the particular tumour microenvironment. The here used anti-HER2 agent is a single-domain antibody or nanobody that targets HER2 with nanomolar affinity but with a size that is ten-fold smaller than conventional antibodies. This could be an important factor in diagnostic and even therapeutic efficacy for nanobody radiopharmaceuticals. The 68Ga-anti-HER2 VHH1 has been successfully tested in phase I trial in 20 breast cancer patients, confirming safety and tolerability, low irradiation burden for PET/CT procedures and high uptake in HER2-positive lesions. The aim of the current study is to test its application potential for PET/CT imaging of breast cancer brain metastases. If favourable, this would support the development therapeutic analogues for targeted radionuclide therapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.081
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 1ODouble PIK3CA mutations in cis enhance PI3Kα oncogene activation and
           sensitivity to PI3Kα inhibitors in breast cancer
    • Authors: Vasan N; Razavi P, Johnson J, et al.
      Abstract: Background: Activating mutations in PIK3CA, the gene coding for the catalytic subunit (p110α) of phosphoinositide-3-kinase (PI3K), are the most frequent oncogenic alterations in oestrogen receptor-positive (ER+) breast cancer and are also prevalent in other tumour types. PI3Kα inhibitors have recently been shown to be clinically active in ER+ breast cancers harbouring PIK3CA mutations. In early clinical trials we had observed that there was also a population of patients that displayed deep and prolonged clinical benefit. In one such patient, whose tumour we had fully genomically characterized, we detected the presence of double PIK3CA mutations in all metastatic sites and at different times over tumour evolution (Juric, Castel, and Scaltriti Nature 2015).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 155PPooled efficacy analysis of first-line ribociclib (RIB) plus endocrine
           therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)
    • Authors: Tripathy D; Hortobagyi G, Chan A, et al.
      Abstract: Background: In 3 Phase III trials, RIB (cyclin-dependent kinase 4/6 inhibitor) + various ET partners demonstrated longer progression-free survival (PFS) vs placebo (PBO) + ET in patients (pts) with HR+/HER2– ABC. Using pooled trial data from the MONALEESA–2 (ML-2; all patients), ML-3 (ET-naïve subgroup only), and ML-7 (NSAI subgroup only) trials, we further evaluate efficacy in ET-naive pts here.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 133PA nomogram for predicting the malignant diagnosis of BI-RADS US
           category 4A lesions in women with dense breast tissue
    • Authors: Yang Y; Hu Y, Shen S, et al.
      Abstract: Background: Biopsy has been the recommended for BI-RADS category 4A, 4B and 4C. However, the malignancy rate of 4A lesions is very low (2-10%). Therefore, the majority of biopsies of category 4A lesions are benign it would take unnecessary costs and make patients anxiety. This study aimed to establish a nomogram, incorporating ultrasound and mammographic as well as patients’ information, to predict the individual likelihood of malignancy of BI-RADS US 4A lesions in diagnostic setting of women with dense breast. To identify patients at lower risk of malignancy and thus avoid unnecessary biopsy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 20PERBB2 mRNA as predictor of response to anti-HER2 antibody-drug
           conjugates (ADC) in breast cancer (BC)
    • Authors: Griguolo G; Brasó-Maristany F, Pascual T, et al.
      Abstract: Background: Quantitative measurements of HER2 might identify the probability to respond to anti-HER2 ADCs better than semi-quantitative methods such as immunohistochemistry (IHC).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.019
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 67PDifferential regulation of glucocorticoid receptor signaling in
           luminal, triple negative and HER2+ breast cancer cells
    • Authors: Zhidkova E; Maksimova V, Lylova E, et al.
      Abstract: Background: Glucocorticoids (GC) are frequently used in the adjuvant treatment of breast cancer (BC). However, they develop numerous side effects including survival of resistant tumor subclones and promotion of metastasis. Biological response to GCs is mediated by glucocorticoid receptor (GR) regulating gene expression via transactivation (TA) associated with side effects of GC, and transrepression (TR), negative interaction between GR and transcription factors. The aims of this study were to investigate: 1) mechanisms of different GC treatment response in different BC cells subtypes; 2) effects of novel selective GR agonist Compound A (CpdA) on BC cells.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.066
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 154OImpact of objective response (OR) on patient-reported outcomes (PRO)
           in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2
           (gBRCA) mutation in the phase III EMBRACA trial
    • Authors: Fasching P; Quek R, Bhattacharyya H, et al.
      Abstract: Background: In EMBRACA, a randomised 2:1 phase 3 open-label study of pts with ABC and a gBRCA mutation, a statistically significant higher OR rate was observed with talazoparib (TALA) (n = 219) vs physician’s choice of chemotherapy (PCT; n = 114) (62.6% vs 27.2%; odds ratio, 5.0; 95% CI, 2.9, 8.8; P < 0.001). To evaluate the effects of OR on PRO, we performed post hoc analyses between pts who had OR vs those who did not, based on both treatments combined as well as for each treatment separately.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 113PThe aromatase inactivator exemestane suppresses serum leptin levels
           significantly in vivo - in contrast to the aromatase inhibitor letrozole
    • Authors: Bahrami N; Jabeen S, Sauer T, et al.
      Abstract: Background: The aromatase inhibitor letrozole (Femarâ/ Femaraâ) and the aromatase inactivator exemestane (Aromasinâ) are currently widely used to treat estrogen receptor positive breast cancer in postmenopausal patients. Interestingly, exemestane may cause clinical disease stabilization following progression on non-steroidal AIs in patients with metastatic breast cancer indicating that additional effects, not necessarily related to estrogen-suppression, may be involved in the well-known “lack of cross-resistance”. The adipocytokine leptin has been shown to enhance the expression of aromatase via promoter II and I.3 using an AP-1 motif. In this study, we evaluated the serum levels of 12 adipokines relative to given treatment with aromatase inhibitors aiming for a direct head-to-head comparison between letrozole and exemestane in vivo.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • Translational Research Index
    • Abstract: AcH3: 179P
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz149
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 132PSurgical management of breast cancer in BRCA mutation carriers: A
           single centre experience
    • Authors: Fachinetti A; Chiappa C, Vischi S, et al.
      Abstract: Background: The optimal local therapy for women with BRCA-associated breast carcinoma remains controversial, and still controversial is the prognostic role of controlateral prophylactic mastectomy (PCM). The aim of this study was to investigate the role of risk reductive surgery in BRCA patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 45P3D association of ER, PR and HER2 to aid sub-grouping of breast cancer
           patients
    • Authors: Zhang J; Lv J, Yu G, et al.
      Abstract: Background: The success of molecular subtyping leads to numerous prognostic algorithms for personalized treatment of breast cancer patients. However, until now, immunohistochemistry (IHC)-based subtyping method still plays a dominant role in daily clinical practice. The discordance between mRNA based and protein based method is well recognized in the field. In this study, we aimed to reconcile these two types of subtyping methods by measuring ER, PR, Her2 and Ki67 as absolute and continuous variables in 1048 Formalin Fixed Paraffin Embedded (FFPE) specimens.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.044
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 149OOutcome and mutational landscape of patients with PIK3CA-mutated
           metastatic breast cancer (mBC)
    • Authors: Mosele M; Lusque A, Tran Dien A, et al.
      Abstract: Background: In a recent study, α-selective PI3K inhibitor improved outcome in PIK3CA mutated HR+/Her2- mBC. Thus, to optimally position PI3K inhibitors, we have investigated the natural history of PIK3CA mutated BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 66PDual targeting of RANKL/RANK pathway and HER-2 as a novel treatment
           strategy in HER-2 positive (+) breast carcinomas (BC)
    • Authors: Zoi I; Xingi E, Thomaidou D, et al.
      Abstract: Background: HER-2 is overexpressed in 20–30% of BC, indicating poor prognosis. RANKL/RANK pathway is implicated in HER-2(+) BC. The molecular mechanism and the potential dual targeting have been evaluated and showed promising results.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.065
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • LBA 1miRNA expression profiles in BRCA1-associated breast cancers reveal
           upregulation of specific miRNAs in tumors lacking a clear second hit in a
           large proportion of the tumour
    • Authors: Heetvelde M; Bockstal M, Dorpe J, et al.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz118
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 84TiPHER-Seq: A blood-based genomic screening study to identify HER2
           mutation-positive patients for enrollment into clinical trials with the
           pan-HER inhibitor neratinib
    • Authors: Tomasevic Z; Smyth L, Saura C, et al.
      Abstract: Background: Somatic mutations in HER2 (ERBB2), in the absence of HER2 amplification, are oncogenic and occur in ∼3% to 5% of solid tumors. HER-Seq (PUMA-NER-9501; ClinicalTrials.gov NCT03786107) is an international genomic screening study for the identification of patients with HER2-mutant breast or cervical cancer, who may be eligible for neratinib clinical trials. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has reported clinical activity in HER2-mutant cancers, with the greatest efficacy observed in breast and cervical cancer. The ongoing Phase II SUMMIT trial for HER2-mutant cancers examines the safety and efficacy of neratinib as monotherapy or in combination (ClinicalTrials.gov NCT01953926; EudraCT 2013-002872-42). Identification of somatic HER2 mutations using a rapid and minimally-invasive test offers a novel therapeutic opportunity for this rare molecular cancer subtype.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.080
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 180PPalbociclib in daily clinical use: Real world experience of the breast
           center at the University Hospital Munich
    • Authors: Hester A; Koenig A, Dobler F, et al.
      Abstract: Background: Since its approval in Europe in November 2016, the CDK4/6 inhibitor palbociclib (PA) has been widely used for treatment of hormone receptor-positive (HR+) metastatic breast cancer (MBC). This study evaluates as a quality assurance measure the treatment with PA at the breast center of the University of Munich (LMU).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.031
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 153OResponse rate by geographic region in patients with hormone
           receptor-positive, human epidermal growth factor receptor-2–negative
           advanced breast cancer from the SOLAR-1 trial
    • Authors: Loibl S; Conte P, Campone M, et al.
      Abstract: Background: In patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC), approximately 40% have tumors that exhibit PIK3CA mutations, resulting in phosphatidylinositol 3-kinase (PI3K) pathway hyperactivation. Use of the oral α-specific PI3K inhibitor alpelisib (ALP) + fulvestrant (FUL) significantly improved progression-free survival (PFS) in pts with ABC and a PIK3CA mutation (hazard ratio [HR]=0.65; P < 0.01) in SOLAR-1, a phase 3, randomized, double-blind study in men and postmenopausal women with HR+, HER2– ABC that progressed on or after aromatase inhibitor treatment. Here we report results by major region from SOLAR-1.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 19PThe clinical impact of substituting multigene assays: Comparative
           clinical analysis of PAM50-ROR versus 21-gene assay
    • Authors: Markopoulos C; Hochheiser L, Hornberger J, et al.
      Abstract: Background: The National Cooperative Cancer Network Guidelines (v3.2018, Oct 2018) state that 21-gene assay (Oncotype DX Breast Recurrence Score®, Genomic Health, Inc.) is the preferred multigene assay (MGA) to predict chemotherapy (CT) benefit for early stage breast cancer (ESBC). We assessed the potential effects of substituting another MGA, PAM50-ROR (Prosigna®, NanoString), for the 21-gene assay on clinical outcomes.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.018
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 112PNomogram for predicting axillary lymph node pathological complete
           response after neoadjuvant chemotherapy in node-positive breast cancer
           patients
    • Authors: Wang W; Wang X, Liu J, et al.
      Abstract: Background: Pathological complete response (pCR) of axillary lymph nodes (ALNs) is frequently achieved in patients with clinically node-positive breast cancer after neoadjuvant chemotherapy (NAC), and ALN status is an important prognostic factor in breast cancer patients. Our goal is to develop a new clinical predictive model to assess the axillary lymph node pCR probability after NAC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 179PRegulation of MMP9 expression by human arylamine N-acetyltransferase
           (NAT1) via Hif-1a
    • Authors: Li P; Minchin R, Butcher N.
      Abstract: Background: Metastatic disease remains a major cause of mortality in breast cancer and previous studies have shown that arylamine N-acetyltransferase 1 (NAT1) is associated with increased cancer spread and poorer outcomes in breast cancer patients. However, the mechanism remains largely unknown. NAT1 alters cancer cell survival and invasive capacity in vitro. Since breast cancer cell invasion has been associated with increased matrix metalloproteinase 9 (MMP9) expression, we investigated the effects of NAT1 on MMP9 expression and activity in a range of cancer cells.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.030
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 131PA prospective comparative study of sentinel lymph node biopsy with
           indo-cyanine green (ICG) florescence technique versus dual dye technique
           for early breast cancer: Going beyond the horizon
    • Authors: Kr A; Sp S, Kumar R.
      Abstract: Background: The dual technique with radio colloid and blue dye is the gold standard in sentinel lymph node biopsy (SLNB) to stage axilla in breast cancer. The objective of the present study was to assess the diagnostic performance of sentinel lymph node (SLN) biopsy using the indocyanine green (ICG) fluorescence method compared with that using the conventional method in detection of sentinel lymph nodes.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • LBA 3A pragmatic, randomised, multicentre trial comparing 4-weekly vs.
           12-weekly administration of bone-targeted agents (denosumab, zoledronate
           or pamidronate) in patients with bone metastases
    • Authors: Clemons M; Stober C, Mates M, et al.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz118.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 44PPrognostic value of Ki-67 in patients with triple-negative breast
           cancer receiving neo-adjuvant or adjuvant chemotherapy: A systematic
           review and meta-analysis
    • Authors: Zhou Q Li W.
      Abstract: Background: Ki-67 is a widely used marker of tumor proliferation, but the prognostic value of Ki-67 in triple-negative breast cancer (TNBC) is still controversial. The aim of present meta-analysis was conducted to evaluate the association between Ki-67 expression and survival in TNBC patients receiving neo-adjuvant or adjuvant chemotherapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.043
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 152OFirst report of AURORA, the breast international group (BIG) molecular
           screening initiative for metastatic breast cancer (MBC) patients (pts)
    • Authors: Aftimos P; Antunes De Melo e Oliveira A, Hilbers F, et al.
      Abstract: Background: MBC remains an incurable disease and the second cause of cancer mortality for women worldwide. While evidence supports molecular evolution of the disease during its life cycle, few molecular profiling studies provide comprehensive longitudinal molecular and clinical data.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 65PmiR-210 and miR-152 as biomarkers in invasive ductal carcinoma by
           liquid biopsy
    • Authors: Zuccari D; Lopes B, Ventura F, et al.
      Abstract: Background: The detection of circulating biomarkers by liquid biopsy is of great importance for early diagnosis and prognosis and, thus, can contribute to decreasing the mortality rate of women with breast cancer (BC). The high mortality of BC is related to the occurrence of metastasis, a process that is associated with angiogenesis. The angiogenic process, in turn, is related to the stimulation of pro-angiogenic factors (among them: Insulin-like Growth Factor 1 Receptor - IGF-1R; Hypoxia-Inducible Factors 1α - HIF-1α and Vascular Endothelial Growth Factor - VEGF) and inhibition of anti-angiogenic factors (such as Von Hippel-Lindau protein - VHL). In addition, the regulation of this neovascularization by epigenetic mechanisms involving microRNAs (miRs) is being investigated and, in BC, oncomiR-210 and the tumor suppressor microRNA-152 stand out in this process.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.064
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 83TiPRESCUE: Reaching for evidence-based chemotherapy use in endocrine
           sensitive breast cancer - A prospective non-interventional study on risk
           assessment by the endopredict test and long-term patient outcome in early
           luminal breast cancer
    • Authors: Ettl J; Blohmer J, Denkert C, et al.
      Abstract: Background: Hormone-receptor (HR) positive, HER2-negative breast cancers make up about 60 % of the primary tumors. For these patients with 0 or up to 3 positive lymph nodes, the indication for chemotherapy is based on an accurate risk stratification. In this situation, conventional clinicopathological parameters are often not suitable for selecting those patients who would not benefit from adjuvant chemotherapy. The EndoPredict test combines a molecular signature with clinical risk factors such as tumor size and nodal status and stratifies patients into “low” or “high” risk groups and thereby improves decision-making. The EndoPredict test can predict the 10-year risk of distant metastases in patients with HR+/HER2- primary breast cancer with endocrine treatment (Evidence level I-B).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.079
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 18PSecondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as
           an actionable target
    • Authors: Duso B; Poletti C, Curigliano G, et al.
      Abstract: Background: HER2-targeting agents are standard of care for the treatment of HER2+ breast cancer (BC), but resistance inevitably occurs and the underlying molecular mechanisms remain poorly characterized. The comparison between mutational profiles of primary (treatment-naïve) and metastatic (who will mostly have received multiple courses of HER2-targeting agents) tumors can inform the search for resistance-inducing genetic alterations to be modeled in vitro and in vivo.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.017
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 111PSubtype-guided 18F-FDG PET/CT in tailoring axillary surgery among
           node-positive breast cancer patients treated with neoadjuvant
           chemotherapy: A feasibility study
    • Authors: Wu S; Wang Y, Li J, et al.
      Abstract: Background: With the increased use of neoadjuvant chemotherapy (NAC), as well as increasing efficacy of systemic therapy, a substantial proportion of clinically node-positive patients may achieve a nodal pathologic complete response (pCR) with chemotherapy. Instead of axillary lymph node dissection (ALND), a novel surgical technique called targeted axillary dissection (TAD) including removal of sentinel lymph nodes (SLNs) and clip-marked node has been gaining acceptance in recent years. Logically, preoperative identification of patients with pCR or residual disease would allow for the optimization of axillary surgery for performing a TAD or proceeding to a ALND after NAC, thus sparing patients unnecessary procedures or expense. The aim of this study was to investigate the value of 18F-FDG PET/CT in tailoring axillary surgery by predicting nodal response among node-positive breast cancer patients after NAC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 130PIntraoperative radiotherapy with electronic brachytherapy system in
           breast cancer patients: Systematic review
    • Authors: Vasileva M; Kostova-Lefterova D, Maslyankov S, et al.
      Abstract: Background: The long-term effectiveness and cosmetic outcomes after intraoperative radiotherapy (IORT) delivered with Xoft® Axxent® Electronic Brachytherapy (eBx®) System in early breast cancer (EBC) is still under evaluation. This system is available in 11 countries around Europe. We aimed to investigate the experience of the European countries with this system and compare the outcomes with the first results in Bulgaria.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as
           maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic
           breast cancer: Final results of the phase III randomized MAIN-A trial
    • Authors: Guarneri V; Cinieri S, Orlando L, et al.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz118.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 178PIntrahepatic mitomycin C infusion in breast cancer liver metastases
    • Authors: Aarts B; Klompenhouwer E, Dresen R, et al.
      Abstract: Background: The aim of this study was to determine the safety and efficacy of intrahepatic Mitomycin C (MMC) infusion in patients with advanced metastatic breast cancer (mBC) resistant to systemic chemotherapy with liver dominant metastatic disease. We determined factors influencing overall survival.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.029
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 198TiPA randomized, double-blinded, controlled study of tucatinib
           (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab
           (T) in patients with pretreated HER2+ unresectable locally advanced or
           metastatic breast carcinoma (mBC) (HER2CLIMB)
    • Authors: Paplomata E; Bachelot T, Mueller V, et al.
      Abstract: Background: Tucatinib (ONT-380) is a highly selective small molecule inhibitor of HER2 kinase with nanomolar potency. Because tucatinib does not inhibit EGFR at clinically relevant concentrations, it potentially decreases EGFR-related toxicities (severe skin rash, diarrhea). In preclinical studies, tucatinib has demonstrated synergistic activity with T and is active in HER2+ models of brain metastases (BM). In a Phase 1b study, tucatinib showed encouraging antitumor activity when combined with C and T in pts with HER2+ mBC previously treated with ado-trastuzumab emtansine (T-DM1) and T. Objective responses were seen, including in pts with BM. The combination was well tolerated with low rates of Gr 3 diarrhea at the recommended dose (300 mg PO BID, equivalent to the single agent MTD). Tucatinib is being evaluated in an ongoing international randomized, double blind, phase 2 study in combination with C and T (HER2CLIMB).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.049
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 43PCIP2A as a novel target to combat basal like breast cancer
    • Authors: Nagelli S; Laine A, Suomi T, et al.
      Abstract: Background: Although both kinases and phosphatases have equally important roles in maintaining cellular homeostasis, the protein phosphatases are understudied and their functional relevance in human malignancies is not fully understood yet. This project aims to better understand the role of a major serine threonine phosphatase called protein phosphatase 2A (PP2A) in cancer particularly basal-like breast cancer (BLBC). BLBC is the most challenging breast cancer subtype as it is very aggressive with no targeted therapies, and the main reason can be attributed to poor understanding of the molecular mechanisms that drive this cancer subtype. Hence, there is a critical clinical need to identify new targets and develop novel therapies for this subtype. Our research group discovered CIP2A (cancerous inhibitor of PP2A) (Cell, 2007) and its role as an oncoprotein in breast cancer and several studies have indicated that high CIP2A expression correlates with more aggressive cancer and poor prognosis in the clinic. This project aims to unravel the molecular mechanisms by which CIP2A drives tumour initiation in BLBC and to establish CIP2A biomarker signature which can serve as a predictive and prognostic tool for better clinical management of BLBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.042
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 110PEvaluation of pathological complete response as a trial-level
           surrogate for long-term survival outcomes among triple-negative breast
           cancer patients receiving neoadjuvant therapy
    • Authors: Huang M; Qi C, Ramsey S, et al.
      Abstract: Background: Pathological complete response (pCR) is a commonly used endpoint in neoadjuvant trials for breast cancer (BC). A pooled analysis sponsored by FDA (Cortazar et al, 2014) showed pCR is a significant predictor of survival outcomes; however, it found little association between magnitude of difference in pCR rates and difference in survival between treatment arms in general BC or triple negative BC (TNBC). To reflect more recent evidence, this study aimed to update and focus the evaluation on the trial-level association between pCR and survival outcomes in TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 129PPerioperative factors and complications after delayed reconstruction
           in breast cancer patients in relation to outcome
    • Authors: Dillekås H; Kristoffersen C, Jensen S, et al.
      Abstract: Background: Complications to surgery have been implicated in recurrence in many cancer forms. Methods for breast reconstruction after mastectomy vary substantially in magnitude of surgical trauma. We have previously reported an impact of delayed reconstructive surgery on the relapse dynamics in breast cancer patients. In the current study, our aim was to determine the rate of complications after delayed breast reconstruction, and explore a potential link to oncologic outcome between these events as well as perioperative factors such as use of LMWH.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 151OSingle agent activity of U3-1402, a HER3-targeting antibody-drug
           conjugate, in HER3-overexpressing metastatic breast cancer: Updated
           results from a phase I/II trial
    • Authors: Yonemori K; Masuda N, Takahashi S, et al.
      Abstract: Background: Human epidermal growth factor receptor 3 (HER3) is overexpressed in a variety of solid tumors, including breast cancer. U3-1402 is a HER3-targeted antibody drug conjugate with a novel peptide-based cleavable linker and a potent topoisomerase I inhibitor payload. The ongoing, phase 1/2 study (NCT02980341) is evaluating the safety, tolerability, and efficacy of U3-1402 in HER3-overexpressing metastatic breast cancer (MBC). Here, we report updated results from Dose Escalation and Dose Finding.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 64PIdentification of serum proteome signatures of male breast cancer
    • Authors: Zografos E; Anagnostopoulos A, Papadopoulou A, et al.
      Abstract: Background: Male breast cancer (MBC) is a rare entity accounting for less than 1% of all malignancies in men. To date, little emphasis has been placed on the elucidation of serum protein alterations in male breast carcinogenesis, even though serum represents an attractive, non-invasive source for biomarker discovery.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.063
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 199OLong-term cardiac outcomes of HER2+ breast cancer patients treated in
           the ALTTO trial
    • Authors: Eiger D; Ponde N, Agbor-Tarh D, et al.
      Abstract: Background: Dual HER2 blockade with trastuzumab (T) and lapatinib (L) is approved for patients (pts) with T-resistant HER2+ metastatic breast cancer, although little is known regarding the cardiotoxicity of this combination. Thus, we report cardiac data on 4,190 pts treated with 1 year of adjuvant T or concomitant T+L in ALTTO (BIG 206/N063D/EGF106708) trial.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 82TiPSCAN-B-rec: Infrastructure, technology and clinical research platform
           to profile and monitor metastatic breast cancer
    • Authors: Bosch A; Larsson A, Holm K, et al.
      Abstract: Background: Great advances have been made in the molecular characterisation of advanced breast cancer (ABC). Still, clinical practice has not changed in terms of assessment of response to therapy. Radiologic imaging and clinical examination help determine disease burden and treatment efficacy. However, imaging heavily relies on the expertise of the radiologist and oncologist and has high intra- and inter-reader variability. Circulating tumor cells (CTCs) enumeration with CellSearchâ has confirmed independent prognostic value compared to conventional radiology and serum markers such as CA15-3. Similarly, quantification of circulating tumor DNA (ctDNA) has also prognostic value in ABC. ctDNA analysis further provides critical information on the mutational status of specific genes which can predict sensitivity to specific targeted therapeutics.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.078
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 17PAre single hormone receptor-positive phenotypes biologically and
           clinically distinct breast cancer' A population-based study
    • Authors: Li Y; Wu Y, Yang D, et al.
      Abstract: Background: Steroid hormone receptors (HRs), estrogen receptor (ER) and progesterone receptor (PR), are crucial biomarkers for clinical management in breast cancer. However, limited data are available regarding single HR-positive, making it difficult for treatment decision and survival prediction in these patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.016
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 177PPertuzumab (P) as ≥ second-line therapy for HER2-positive
           metastatic breast cancer (mBC): Swiss clinical experience
    • Authors: Biskup E; Montavon Sartorius C, Müller A, et al.
      Abstract: Background: P is approved in the EU and US as 1st-line therapy in combination with docetaxel and trastuzumab (H) for HER2-positive mBC based on phase III results (CLEOPATRA). Data in later lines are very limited. In Switzerland, national regulations allow physicians to use P in this setting. We identified P-naïve patients (pts) treated with ≥2nd-line P+H in Switzerland to gain insight on clinical outcomes with P beyond 1st line.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.028
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 42P_PRPainting the global picture of HER2-testing for breast cancer. The
           ONCOLLEGE-001 survey study
    • Authors: Altuna S; Lengyel C, Trapani D, et al.
      Abstract: Background: Breast cancer (BC) is the most common cancer in women and the leading cause of cancer-related death. HER2 is overexpressed in approximately 15-20% of BCs. HER2 expression is not only a prognostic biomarker but a predictive biomarker of response to HER2 targeted therapies. The ONCOLLEGE-001 project addresses the distribution & disparities of HER2-testing (H2T) methods (IHC or in situ hybridization (ISH), which may use either fluorescent (FISH), chromogenic (CISH) or silver (SISH) detection method) in breast cancer, with the aim of painting the global picture (GP).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.041
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 109PEarly prediction of non-pCR using ultrasound-guided serial core needle
           biopsy in HER2-positive breast cancer patients
    • Authors: Zhang Y; Shen J, Zhou Y, et al.
      Abstract: Background: Pathological complete remission (pCR) distinguishes the prognosis of breast cancer patients undergoing neoadjuvant chemotherapy (NAC). On the contrary, non-pCR patients have poorer prognosis and may benefit from escalation or alteration of systemic therapy. Early and accurate identification of non-pCR remains a focused issue.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 197TiPPhase III study of [fam-] trastuzumab deruxtecan vs investigator’s
           choice in T-DM1-pretreated HER2+ breast cancer
    • Authors: André F; Shahidi J, Lee C, et al.
      Abstract: Background: There is no uniform standard of care for HER2+ breast cancer (BC) after disease progression on T-DM1. [Fam-] trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanized HER2 antibody, topoisomerase I inhibitor payload, and cleavable peptide-based linker. In an ongoing phase 1 trial, [fam-] trastuzumab deruxtecan showed promising antitumor activity in T-DM1-pretreated HER2+ BC (confirmed objective response rate [ORR] of 54.5%; April 2018 data cutoff). The pivotal, phase 2 DESTINY-Breast01 trial in this population is ongoing.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.048
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 128PRole of short-course radiotherapy in post-operative carcinoma of the
           breast
    • Authors: Behera M; Mittal K, Dutta S, et al.
      Abstract: Background: Accelerated hypofractionated or conventional RT post BCS reoprted similar recurrence rates and cosmetic outcomes. Conventional RT delivers radiation dose of 50 Gy in 25 fractions in 5 weeks. Radiobiologic models suggests higher radiation doses over shorter period of time may produce similar outcomes. An accelerated, hypofractionated treatment also might be more convenient for patients and conserve resources, in developing countries where patient load is too much and the resources are limited.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 63PControlling nutritional status (CONUT) score is a prognostic factor in
           patients with resected breast cancer
    • Authors: Li W; Deng Y, Ma G, et al.
      Abstract: Background: Controlling nutritional status (CONUT), as an index to measure a patient’s nutritional condition, was found to be correlated with outcomes of various cancers. However, its prognostic role in breast cancer patients with curative resection remains unclear. Hence the present study was designed to determine the correlation between CONUT and prognosis in resected breast cancer patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.062
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 219TiPFeasibility of a self-screening for insomnia and acceptability of an
           online targeted video-based cognitive behavioral program in cancer
           outpatients: SLEEP-4-ALL-1 study design
    • Authors: Charles C; Boinon D, Fasse L, et al.
      Abstract: Background: Insomnia is a distressing and an enduring problem that affects between 25 and 59% of cancer patients during and after treatments. Despite its association with reduced quality of life, negative psychological symptoms and cancer-related fatigue, this major concern remains insufficiently assessed and managed in routine care. Cognitive-Behavioural Therapy for Insomnia (CBT-I) is considered as the non-pharmalogical gold standard treatment. However, one main limitation is the practical implementation of the intervention because of the lack of trained professionals in cancer care settings and geographic distances from therapeutics resources. The frequent presence of somatic comorbidities, such as fatigue or pain, can also complicate access to care. New technologies open innovative ways to facilitate access to targeted interventions, such as online attractive and easy-to-use programs.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.020
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 41PPrognostic significance of BCL-2 expression in triple negative breast
           cancer (TNBC)
    • Authors: Srinivasalu V; Susan A, Jose W, et al.
      Abstract: Background: B- Cell lymphoma (BCL-2) is a antiapoptotic protein and an important clinical breast cancer prognostic marker but however its expression differs according to the molecular subtype and is reported to be a good marker only in Luminal A type. We aimed to assess its prognostic significance in patients with TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.040
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 16PLongitudinal HER2 amplification tracked in circulating tumor DNA for
           therapeutic effect monitoring and prognostic evaluation in patients with
           breast cancer
    • Authors: Guan X; Niu Y, Liu B, et al.
      Abstract: Background: Human epidermal growth factor receptor 2 (HER2) status is a crucial predictive factor for prognostic assessment and targeted therapy selection, which may be influenced by intratumor heterogeneity and molecular divergence between the primary site and different metastases. Therefore, we performed a prospective study to confirm the concordance of HER2 amplification in circulating tumor DNA (ctDNA) with primary tumor tissue and verified its clinical implications.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.015
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 176PBrain metastasis of breast cancer: A 10-year single institution
           retrospective analysis
    • Authors: Batista M; Tomás T, Eiriz I, et al.
      Abstract: Background: In cohort studies, estimated incidence of breast cancer (BC) brain metastases (BM) is about 5%. This number seems to be increasing, due to longer survival. We intend to characterize the population of breast cancer patients treated in a single institution who developed BM in a 10-year-period.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.027
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 86ODose-dense adjuvant chemotherapy in early breast cancer: 15–year
           results of the phase III Mammella InterGruppo (MIG)-1 study
    • Authors: Blondeaux E; Cantore M, Michelotti A, et al.
      Abstract: Background: Dose dense adjuvant chemotherapy is the preferred treatment option in high-risk early breast cancer patients. We report the updated results of the MIG-1 study comparing the efficacy of fluorouracil, epirubicin and cyclophosphamide (FEC) regimen administered every 3 (FEC21) or every 2 (FEC14) weeks in early breast cancer patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both
           followed by T-DM1 in case of progression in patients with HER2-positive
           metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a
           randomized open label phase II study (SAKK, UNICANCER, BOOG)
    • Authors: Huober J; Ribi K, Weder P, et al.
      Abstract: Background: We assumed that a strategy with dual blockade of T+P without chemotherapy followed by T-DM1 at progression might be similarly effective in terms of overall survival (OS), but less toxic resulting in better Quality of Life (QoL) in pts with HER2+ MBC. Updated efficacy results by hormone receptor (HR) status and QoL data are given.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 81PInotilone interferes with chromosome replication as an attractive
           anti-cancer drug target for breast cancer
    • Authors: Chen L; Tu S, Ho Y.
      Abstract: Background: The function of DNA primase is to synthesize the small RNA primers for Okazaki fragments generated during discontinuous DNA replication. This primase is required because DNA polymerases cannot initiate RNA polymer synthesis and they can elongate polymers only using RNA polymers that have already been synthesized. Eukaryotic cells contain PRIM1 and PRIM2 subunits of nuclear DNA primase. PRIM1 is the smallest subunit of the heterotetrameric eukaryotic Pol alpha/primase complex. It alone carries the catalytic function of the enzyme and can elongate primers, whereas PRIM2 does not exert such enzymatic activity.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.077
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of
           ladiratuzumab vedotin (LV) in combination with pembrolizumab for
           first-line treatment of patients with unresectable locally-advanced or
           metastatic triple-negative breast cancer
    • Authors: Boni V; Alemany C, Meisel J, et al.
      Abstract: Background: Patients with metastatic triple negative breast cancer (mTNBC) subtype have poor outcomes with a median overall survival (OS) of approximately 1 year. SGN-LIV1A, or ladiratuzumab vedotin (LV), is an investigational monomethyl auristatin E (MMAE)-conjugated humanized IgG1 antibody-drug conjugate (ADC) against LIV-1, a highly expressed transmembrane protein in breast cancer cells. LV mediated delivery of MMAE drives antitumor activity through cytotoxic cell killing and has been shown to induce immunogenic cell death (ICD). Preliminary results from an ongoing phase 1 study show that LV monotherapy is well tolerated and has encouraging antitumor activity in patients with mTNBC. Pembrolizumab, a checkpoint inhibitor that elicits antitumor activity by targeting the T cell inhibition pathway, showed limited response in the treatment of locally advanced/metastatic (LA/M) TNBC as monotherapy. Combining LV and pembrolizumab may result in synergistic activity through LV-induced ICD that creates a microenviroment favorable for enhanced anti-programmed cell death protein 1 activity.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.047
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 127PTreatment outcomes after post-operative radiotherapy in
           triple-negative breast cancer: Multi-institutional retrospective study
           (KROG 17-05)
    • Authors: Kim J; Byun S, Shin K, et al.
      Abstract: Background: Triple-negative breast cancer (TNBC) shows different clinical course from ER-positive cancers. We designed multi-institutional retrospective study to analyze treatment outcomes after post-operative radiotherapy in TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 62PGrowth inhibition of triple-negative breast cancer cells due to the
           lack of CD73
    • Authors: Petruk N; Sandholm J, Tuomela J, et al.
      Abstract: Background: Among breast cancer patients, 10-20 % have triple-negative breast tumors (TNBC) and bear the worst prognosis due to the lack of targetable proteins: ER, PR, and Her2. CD73 is a nucleotidase, which converts AMP to adenosine and involved in many processes, such as promotion of cancer cell proliferation, migration and tumor immunoescape. We and others have shown previously that TNBC patients with low tumor TLR9 expression had significantly worse breast cancer-specific survival, as compared with TNBC patients whose tumors had high TLR9 expression upon diagnosis. TLR9 and CD73 expression have demonstrated mutual regulation in immune cells in certain disease conditions, such as diabetes. However, the mutual relationship of these proteins has not been investigated in cancer. The aim of this study was to investigate whether CD73 and TLR9 have mutual effects in TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.061
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 15PInfluence of PIK3CA mutations on breast cancer proliferation,
           lymphocyte infiltration and clinical outcome: Pooled analysis of 484
           patients from three prospective multicentre GBG trials
    • Authors: Jank P; Loibl S, Fasching P, et al.
      Abstract: Background: The PI3K signaling pathway is frequently dysregulated in breast cancer (BC), effected through mutations in PIK3CA, which encodes for the catalytically subunit p110-alpha. An influence of PIK3CA mutations in therapy response resistance associated with a worse clinical outcome has previously been shown in HER2+ BC. Mutations in exon 9 or 20 may play a role in cell proliferation and therapy response.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 40PWNT, Hedgehog and NOTCH signaling pathways in triple negative breast
           cancer with high and low content of cancer stem cells
    • Authors: Brilliant A; Brilliant Y, Sazonov S.
      Abstract: Background: Triple negative breast cancer is at the greatest interest for the study. Cells of this type of breast cancer do not have receptors for steroid hormones or tyrosine kinases. For successful treatment of triple negative cases additional points of application are needed. Such targets could be cancer stem cells. For these types of cells, as well as for other stem cells, there are three main cascades are typical - WNT, Hedgehog and NOTCH. However, the conducted studies indicate the existence of other signaling mechanisms of regulation. In our work, we investigated the expression of the NF-kB, PI3K signaling pathways, as well as WNT, Hedgehog, NOTCH in cells of triple negative breast cancer with high and low content of cancer stem cells (ALDH1A1 level).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.039
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 218PFeasibility study of using an app-based mHealth group challenge to
           improve physical activity (PA) and fatigue after breast cancer (BC)
    • Authors: Martin E; Di Meglio A, Charles C, et al.
      Abstract: Background: PA has shown beneficial effects in the treatment of BC fatigue, nevertheless a significant portion of patients (pts) remain insufficiently physically active after BC. Currently most of BC pts has a smartphone and therefore mobile health (mHealth) holds the promise of promoting health behaviors uptake for many of them. Kiplin® developed an app-based mHealth group intervention aiming at engaging pts in group PA challenges while monitoring daily steps. The aim of this study was, through qualitative exploration, to 1) understand the feasibility of this challenge and 2) inform its development in pts with BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.019
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 107PA comparative study of voluntary deep inspiration breath hold versus
           free breathing techniques in adjuvant left breast hypofractionated
           radiotherapy
    • Authors: Elkhouly E; Abdelbarry N, Rashed Y, et al.
      Abstract: Background: Left-sided breast cancer radiation therapy has been associated with an increased risk of major coronary events. There is evidence demonstrating that the increase is proportional to mean heart dose. Deep Inspiration Breath Hold (DIBH) is a radiation therapy technique that has shown significant dose reduction to the heart and lung in hypofractionated radiotherapy of adjuvant left-sided breast cancers. This study explores the potential benefit of utilizing a DIBH technique to reduce heart and ipsilateral lung doses.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.021
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 126PClinical outcome of early stage breast cancer patients with 1 to 3
           positive axillary lymph nodes: A single institution experience
    • Authors: Arjunan A; Abbas S, George P.
      Abstract: Background: There is no definite consensus on the role of post-operative radiotherapy (RT) in breast cancer patients with 1-3 axillary lymph node positivity. EBCTCG meta-analysis and Danish trials (DBCG 82 b and c) showed improvement in loco regional control and overall survival (OS) with post operative radiotherapy in 1-3 node positive patients, but level I evidence is awaited [SUPREMO trial]. With this background we conducted this retrospective analysis to evaluate clinical outcomes of patients with 1 to 3 axillary node positive breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 175PA four-year study of epidemiological trends of breast cancer in a
           Haitian cancer program
    • Authors: Bernard J; Alexis L, Degennaro V.
      Abstract: Background: According to GLOBOCAN 2018, breast cancer is the most common cancer among women in Haiti. However, its trend throughout the years has not yet been studied. This study aims to present the four-year epidemiological trends of breast cancer managed by a cancer program in Port-au-Prince, Haiti.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.026
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 61PFounder mutations BRCA2 c.156_157insAlu in Portuguese population
    • Authors: Macedo F; Félix Soares R, Cunha Pereira T, et al.
      Abstract: Background: Inherited predisposition to breast cancer (BC) accounts for about 5–10% of all cases. Women carrying germline BRCA2 mutations have a cumulative risk at 70 years of 55% for BC and 17% for ovarian cancer. The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer families of Portuguese origin.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.060
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 106PMolecular sub types of breast cancer in a developing country.
           Classification immunohistochemical: Clinicopathologic feature and survival
           analysis
    • Authors: Castro H; Salazar L, Garcia L, et al.
      Abstract: Background: Breast cancer (BC) is a heterogeneous malignancy and it’s possible to identify by inmmunohistochemistry, four subtypes with different clinical and biological behavior. Our aim was to evaluate the prevalence, disease free survival (DFS) and overall survival (OS) influence of these subtypes on the Guatemalam population.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.020
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 14POutcomes of women at high familial risk for breast cancer in Australia:
           An 8-year single-centre experience
    • Authors: Lammert J; Skandarajah A, Shackleton K, et al.
      Abstract: Background: The value of a high-risk surveillance program for mutation carriers compared to non-carriers at high familial breast cancer risk is not well understood. The Breast and Ovarian Cancer Risk Management Clinic (BOCRMC) was established to provide multimodality screening and risk management strategies. The purpose of this study was to compare breast cancer diagnoses for BRCA1, BRCA2 and other germline mutation carriers versus non-carriers attending the BOCRMC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 195TiPSYNERGY: Phase I and randomized phase II trial to investigate the
           addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and
           carboplatin for previously untreated, locally recurrent inoperable or
           metastatic triple-negative breast cancer (TNBC)
    • Authors: Maurer C; Eiger D, Velghe C, et al.
      Abstract: Background: The combination of immune checkpoint blockade and chemotherapy has improved overall survival in a limited subset of patients (pts) with metastatic TNBC. The ectoenzyme CD73 found on the surface of tumor and stromal cells has immunosuppressive functions and is associated with poor prognosis in TNBC, thus blocking it with the monoclonal antibody oleclumab might enhance antitumor response of combined immunotherapy and chemotherapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.046
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 38PDefining the physiological miRNA landscape in nipple aspirate fluid
    • Authors: Patuleia S; Moelans C, van Gils C, et al.
      Abstract: Background: MicroRNAs (miRNAs) are small, non-protein-coding RNAs that can bind and suppress specific target messenger RNAs (mRNAs). Their dysregulation has been shown to affect the hallmarks of cancer and an increasing number of studies have identified miRNAs as potential biomarkers for cancer diagnosis. The ability to detect local oncogenic or tumor suppressor miRNAs in nipple aspirate fluid (NAF) could be of great value for early breast cancer diagnosis. To define the landscape of miRNAs physiologically present in the breast ducts, we analyzed their expression patterns in healthy NAF samples.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.037
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 144PImmune cell dynamics induced by a single dose of pembrolizumab as
           revealed by single-cell RNA profiling
    • Authors: Vos H; Bassez A, Qian J, et al.
      Abstract: Background: To improve our understanding of the molecular mechanisms underlying response to immune checkpoint inhibition, we monitored dynamic changes within the tumour microenvironment exposed to immune checkpoint inhibition by single-cell RNA sequencing (scRNA-seq).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz099
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 80PDNA methylation markers of breast cancer response to anthracycline
           based neoadjuvant chemotherapy
    • Authors: Sigin V; Strelnikov V, Litviakov N, et al.
      Abstract: Background: Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of locally advanced breast cancer (BC). The aim of this study is to provide a better insight into BC response to neoadjuvant anthracycline based chemotherapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.076
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 217PFeasibility of quantitative sensory testing (QST) in clinical routine
           as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN)
           amongst breast cancer patients treated with taxanes
    • Authors: Ioannou I; Utpadel-Fischler D, Tölle T, et al.
      Abstract: Background: CIPN represents one of the main dose-limiting and quality of life-affecting factors of taxane therapy in breast cancer patients. Effective therapeutic and prophylactic measures against CIPN are still missing. Aim of this study is to develop a tool, which is capable of evaluating CIPN during chemotherapy and to proof its feasibility in clinical routine.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.018
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 105PSafe chemotherapy for treating early breast cancer in G6PD-deficient
           patients
    • Authors: Donisi C; Atzori F, Dessì M, et al.
      Abstract: Background: The aim of this study is to evaluate the hematologic and non-hematologic toxicity of adjuvant treatment with anthracyclines in G6PD deficient patients affected by breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.019
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 125P Brazilian randomized study: Impact of preoperative magnetic resonance
           in the evaluation for breast cancer conservative surgery (BREAST-MRI
           Trial)
    • Authors: Mota B; Reis Y, Doria M, et al.
      Abstract: Background: Breast magnetic resonance imaging (MRI) has a high sensitivity (95-100%) in detecting invasive neoplasms. Controversy still exists whether preoperative staging with breast MRI has an impact on surgical outcomes. The aim of this randomized controlled trial is to evaluate the ability of MRI in selecting patients for breast conserving surgery (BCS).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 174PThe outcome of patients with metastatic breast cancer with lung
           metastasis treated with fulvestrant is superior to that of those with
           liver metastasis
    • Authors: He M; Li J, Zuo W, et al.
      Abstract: Background: Endocrine therapy is the preferred treatment for patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of metastases at different visceral sites.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.025
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 60PAnti-inflammatory treatment and inhibition of B-cell activation in a
           nude mouse model of human breast cancer
    • Authors: Fernandez Madrid F; Maroun M, Long M.
      Abstract: Background: The objective of this work was to demonstrate that the concerted action of tumor-associated antigens [TAAs] and inflammatory cytokines inflict autoimmune damage to the breast creating a chronic inflammatory milieu that promotes breast cancer [BC] progression.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.059
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 194TiPPhase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1
           for HER2-positive breast cancer
    • Authors: Verma S; Shahidi J, Lee C, et al.
      Abstract: Background: [Fam-] trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate (ADC) with a humanized HER2 antibody, topoisomerase I inhibitor payload, and cleavable peptide-based linker. In an ongoing phase 1 trial, [fam-] trastuzumab deruxtecan had a manageable safety profile and promising antitumor activity in HER2+ breast cancer (BC) previously treated with T-DM1 (confirmed objective response rate (ORR) of 54.5%; April 2018 data cutoff). The pivotal, phase 2 DESTINY-Breast01 trial in this population is ongoing.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.045
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 13PDynamic monitoring of ctDNA reveals that acquired NF2 mutations confer
           resistance to HER2 targeted therapy in HER2-mutant breast cancer
    • Authors: Li X; Ma J, Pan B, et al.
      Abstract: Background: Preclinical studies suggest that HER2 mutations lead to constitutive HER2 activation, but knowledge about effective treatment options and clinical resistance mechanisms remain uncharacterized.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 37PRNA signatures from tumor-educated platelets (TEP) enable detection of
           early-stage breast cancer
    • Authors: Liefaard M; Lips E, Best M, et al.
      Abstract: Background: Breast cancer stage at diagnosis has a large impact on the 10-year survival probability. Mammography based screening has enabled early detection of breast cancer. However, mammography has limited sensitivity, and suffers from overdiagnosis and overtreatment. We aim to improve screening by developing a classification algorithm based on mRNA signatures from blood platelets (Tumor Educated Platelets; TEP).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.036
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 216PThe predictive value of NHS PREDICT for triple negative breast cancer
    • Authors: Sobočan M; Belak U, Sikošek Čas N, et al.
      Abstract: Background: Tools to support clinical decision making regarding breast cancer (BC) are becoming more available to clinicians. NHS PREDICT is a freely available web-based tool for prognostication and assistance in BC management. Recent research shows doubt in using the tool for BC subtypes. There is fear over the possibility of over- or undertreatment of patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.017
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 104PFinal results of scalp cooling for hair preservation: A
           single-institution prospective study
    • Authors: Loparco D; Orlando L, Caloro M, et al.
      Abstract: Background: The cancer treatments bring with it body image challenges, causing low self-esteem and contributing to worsen the quality of life. Chemotherapy (CT)-induced hair loss (HL) is one of the most emotionally distressing side effects of several breast cancer (BC) treatments. The DigniCap system (DCS), using the scalp cooling system, has been shown to reduce CT-induced alopecia (A) in a multicenter prospective trial. The purpose of this prospective observational study was to describe our experience.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.018
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 12PDuctal carcinoma in situ of the breast: Immune cell composition
           according to subtype
    • Authors: Agahozo M; Van Bockstal M, Groenendijk F, et al.
      Abstract: Background: Ductal carcinoma in situ (DCIS) of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of DCIS-associated immune cells and their potential role in DCIS progression is limited. We studied DCIS-associated immune response by characterizing immune cell subsets according to DCIS subtypes.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 173PCurrent treatment landscape in triple negative breast cancer: A
           systematic literature review
    • Authors: Fu A; Kuang Y, Fazeli M, et al.
      Abstract: Background: Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer diagnoses. As novel targets and therapies for TNBC emerge, a comprehensive overview of the current landscape of evidence on the approved or developing treatment options was needed.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.024
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 59PMyeloid derived-suppressor cells in healthy women and in advanced
           breast cancer patients
    • Authors: Palazón Carrión N; Sánchez León M, Jiménez Cortegana C, et al.
      Abstract: Background: In advanced breast cancer (ABC) some studies suggest a deleterious effect on survival when high levels of myeloid-derived suppressor cells (MDSC)1,2 are detected in peripheral blood. Furthermore, classical therapies like anthracyclines or gemcitabine seem to exert an immunostimulating effect by eliminating and/or altering the function of MDSC3. The objective of this study is to analyze the evolution of blood MDSC in patients with ABC prior to the standard first-line systemic therapy according to Clinical Practice Guidelines.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.058
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 124PLate-term effects in the arm and shoulder with hypofractionated
           regional nodal irradiation in patients with breast cancer
    • Authors: Yadav B; Bansal A, Philip G.
      Abstract: Background: Hypofractionated radiotherapy (RT) is becoming a new standard in the adjuvant treatment for patients with breast cancer. However, data are lacking on late-term arm and shoulder morbidity with hypofractionation in patients with advanced stage disease who undergo mastectomy followed by local and regional nodal irradiation (RNI). In this study, we report late-term effects in arm and shoulder with 3 weeks of RNI with hypofractionation in patients with breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 148PInvestigation on the MyD88 mediated TLR3 signaling via cell surface in
           breast cancer
    • Authors: Singh A; Basu A, Devkar R.
      Abstract: Background: Toll-like receptor -3 is a nucleic acid-sensing innate immune receptor that detects RNA released from narcotic cells in the tumor microenvironment. TLR3 is expressed on the endosomal compartments but the surface expression of TLR3 has also been reported in various cancers, including breast cancer from our group (Bandopadhya et al., 2015). TLR3 exclusively uses TRIF dependent pathway to mediate its effect on cellular apoptosis and hence used in different clinical trials. But, the outcomes of clinical trials using TLR3 agonists are not always favorable. In the present work, we have addressed the involvement of canonical MyD88 mediated pathway through cell surface to explain the anti-apoptotic effect.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz099.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 36PEndocrine implications in male breast cancer in Bulgaria
    • Authors: Konsoulova-Kirova A; Kalchev K, Yordanov A, et al.
      Abstract: Background: The vast majority of male breast cancers (male BC) are luminal-like hormone receptor (HR) positive invasive ductal carcinomas. Agter surgery, endocrine treatment (ET) therefore should be the mainstay in both adjuvant and metastatic setting. According to the RARECAREnet study, 5-year relative survival until 2007 in Bulgarian male BC patients is 59%, compared to 77 % on average for Europe. We therefore analyze available data from the National Cancer Registry to identify reasons for these low survival rates and aim to assess the role of ET in the management of male BC patients in Bulgaria.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.035
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 215PMale breast cancer, a heterogeneous entity: Experience from a cancer
           center
    • Authors: Carvalho J; Peixoto M, Cunha Pereira T, et al.
      Abstract: Background: Male Breast Cancer (MBC) represents 1% of all breast cancers, as well as less than 1% of malignant neoplasm in male.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.016
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 79PThe adipokine receptor CAP1 regulates breast cancer cell proliferation
    • Authors: Bergqvist M; Borgquist S, Rosendahl A.
      Abstract: Background: The adipokine resistin is linked to insulin resistance and has been shown to be upregulated in breast cancer patients. Previously we demonstrated that high levels of newly identified resistin receptor Adenylate Cyclase-Associated Protein-1 (CAP1) in breast tumors was associated with impaired prognosis. We here aim to delineate the molecular linkage between resistin, CAP1 and breast cancer prognosis.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.075
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 193PPALBOCOMP: Retrospective observational analysis of palbociclib
           treatment in patients with advanced breast cancer within a compassionate
           use program in Spain
    • Authors: Manso L; Bermejo B, Delgado I, et al.
      Abstract: Background: The combination of palbociclib with hormone therapy significantly increases progression free survival (PFS) compared with hormone therapy in first and second treatment line of HR+ HER2- metastatic breast cancer (MBC). However, the activity and security of palbociclib in MBC patients progressing after multiple treatment lines, has not been tested in clinical trials.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.044
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 103PAnti HER-2 therapies and left ventricular dysfunction: A prospective
           study
    • Authors: Daniele A; Gregorietti V.
      Abstract: Background: The Anti Her 2 drugs (AH2D): Trastuzumab (T) and Pertuzumab (P), are very important tool in the treatment of HER2 + Breast Cancer. (BC), who presented left ventricular dysfunction (LVD) in the follow-up. We analysed prospectively a group of p. who presented a LVD after the therapy with an AH2D. We proposed that the early treatment with Beta-Blockers (BB) (Carvedilol), angiotensin-converting enzyme inhibitor (IECA) (Enalapril) or Angiotensin Receptor Blockers (ARBs) (Valsartan), Aldosterone Antagonist (AA) (eplerenone); could to help for an early recovery of left ventricular ejection fraction (LVEF) and to allow the reintroduction of the AH2D without a new risk of LVD.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.017
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 11PMammographic density change and risk of breast cancer
    • Authors: Azam S; Eriksson M, Sjölander A, et al.
      Abstract: Background: Mammographic density (MD) is a strong risk factor for breast cancer. We examined the association between annual MD change and risk of breast cancer, and how adding annual MD change to baseline measure of MD influenced risk prediction of breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 35PDownregulation of immune checkpoints by doxorubicin and
           carboplatin-containing neoadjuvant regimens in breast cancer: A new
           insight into the mechanism of induction of antitumor immunity
    • Authors: Sadighi S; Sharifian R, Kazemimanesh M, et al.
      Abstract: Background: This study aimed to assess the effects of three doxorubicin, paclitaxel or carboplatin-containing neoadjuvant chemotherapy regimens on tumor infiltrating lymphocytes and immune checkpoints in a murine model of triple-negative breast cancer (BC).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.034
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 58PSpindle cell carcinoma of the breast: Rare cancer with potentially
           targetable biomarkers
    • Authors: Gatalica Z; Vranic S, Stafford P, et al.
      Abstract: Background: Spindle cell carcinoma is a rare, metaplastic breast cancer (<1% of all breast carcinomas), with reportedly triple-negative (TNBC: ER-/PR-/Her2-) phenotype, associated with a marked resistance to conventional chemotherapy and overall poor outcome.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.057
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 108OFactors predicting relapse in early breast cancer patients with a
           pathological complete response after neoadjuvant therapy: Pooled analysis
           based on the GBG database
    • Authors: Huober J; Schneeweiss A, Blohmer J, et al.
      Abstract: Background: Although patients with a pathological complete response (pCR) after neoadjuvant chemotherapy have an excellent prognosis, some of them will eventually relapse. A better identification of patients with an increased risk of relapse despite a pCR can help selecting these patients for additional post-neoadjuvant treatment strategies. This retrospective analysis aimed to identify factors predicting relapse despite a pCR.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 214PTrastuzumab related cardiotoxicity in nonmetastatic breast cancer: A
           real-world scenario
    • Authors: Shrivastva S; Prasad S, Chennamaneni R, et al.
      Abstract: Background: Trastuzumab, a humanized monoclonal antibody significantly improves outcomes in Her2 neu positive breast cancer. The incidence of cardiotoxicity with trastuzumab is approximately 8-10%. The present study was designed to analyze the incidence and risk factors associated with trastuzmab related cardiotoxicity.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.015
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 192PPredictive role of derived neutrophil to lymphocyte ratio on
           platinum-based chemotherapy in triple-negative breast cancer
    • Authors: Marra A; Viale G, Trapani D, et al.
      Abstract: Background: Triple negative breast cancer (TNBC) is commonly associated with a poor prognosis. Platinum-compounds (P) and low dose oral cyclophosphamide (mCy) have showed activity in TNBC, exerting a direct cytotoxic and possibly immunomodulating activity. Neutrophil (ANC) to lymphocyte (ALC) ratio (NLR), derived NLR (ANC/[White blood cells − ANC]; dNLR), platelet to ALC ratio (PLR), and high lactate dehydrogenase (LDH) level have been proposed as measures of inflammatory/immunosuppressive status, associated with poor prognosis. The aim of this study is to evaluate these biomarkers in TNBC patients treated with P+mCy combination.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.043
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 172PBreast cancer specific graded prognostic assessment (BC-GPA) score and
           outcome of HER 2 positive breast cancer patients with brain metastases: A
           single centre retrospective analysis
    • Authors: Kate S; Paleja N, Patil R, et al.
      Abstract: Background: Her2 overexpressing breast cancer patients are at a high risk for developing brain metastases. We analysed the group of Her 2 overexpressing patients and studied disease and treatment related characteristics of those with and without brain metastases.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.023
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 147PClinical significance of BCL-2 with basal and non-basal triple
           negative breast cancer (TNBC)
    • Authors: Srinivasalu V; Susan A, Philip A, et al.
      Abstract: Background: B- Cell lymphoma (BCL-2) is a antiapoptotic protein and an important clinical breast cancer prognostic marker but however its expression differs according to the molecular subtype and is reported to be a good marker only in Luminal A type. We aimed to assess its prognostic significance in patients with basal and non-basal TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz099.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 34PComparison of HER2, estrogen and progesterone receptor expression
           profiles of primary tumor and synchronous axillary lymph node metastases
           in 159 breast cancer patients - indicating tumoral heterogeneity
    • Authors: Weydandt L; Horn L, Aktas B.
      Abstract: Background: Several studies have shown that there may be change in the expression of steroid hormone receptors (ER and PR) as well as Her-2 as possible therapeutic relevant targets during disease progression (primary tumor versus metastatic disease). However, it is rarely considered into primary therapy that there can be already differences between the primary tumor and synchronous lymph node metastases (LMN). The aim of the present study was to compare the HER2/ER/PR expression profiles of primary tumors and synchronous LNM.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.033
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 78PAn in vivo genome-wide RNAi screen identifies novel mediators of
           paclitaxel response in breast cancer
    • Authors: Sultan M; Cruickshank B, Huynh T, et al.
      Abstract: Background: Breast cancer treatment often involves the use of paclitaxel to target tumor cells; however, some patients do not respond to treatment and would be better treated with an alternative drug. Thus, being able to identify the genes which when expressed in a tumor predict paclitaxel response prior to administration would improve treatment efficacy and patient survival.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.074
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 102P_PRBreast cancer early recurrences in young women
    • Authors: Cima S; Cekani E, Valli M, et al.
      Abstract: Background: Breast cancer is the most common cause of cancer in women worldwide, with more aggressive clinical behavior and poor outcomes in younger patients. This is to their increased risk of presenting with biologically aggressive types of cancer and at more advanced stage. Many studies have attempted to identify risk factors for local recurrence and distant metastases. The aim of this retrospective study was to analyze rates of recurrence in young patients with breast cancer treated at Ticino Breast Unit.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.016
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 57PPrognostic role of microRNA 182 and microRNA 18a in locally advanced
           triple negative breast cancer
    • Authors: Bajaj R; Doval D, Tripathi R, et al.
      Abstract: Background: Breast cancer is a heterogeneous disease and triple negative breast cancers (TNBC) have higher histological grade, more aggressive locally along with higher chances of distant visceral metastasis. The present study was undertaken to assess the epigenetic regulation in breast cancer and the role of microRNA 182 and microRNA 18a (MIR 182 and MIR 18a) expression in locally advanced TNBC and comparison with the clinico-pathological variables and survival.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.056
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 191PImaging-proven venous thromboembolism among breast cancer patients in
           a tertiary hospital in the Philippines from 2010-2015
    • Authors: Gerona A; Gorospe A.
      Abstract: Background: Venous thromboembolism (VTE) is a common cause of mortality in cancer patients. This paper looks into prevalent characteristic of breast cancer in association with VTE, if any.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.042
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 213PHIV infection in breast cancer patients from Mozambique: A prospective
           cohort study
    • Authors: Brandão M; Guisseve A, Bata G, et al.
      Abstract: Background: Breast cancer (BC) burden is increasing among women living with HIV (HIV+). Yet, data regarding epidemiology, BC presentation, treatment, and prognosis is still scarce, especially among HIV+ BC patients (pts) from developing countries.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 171PGastrointestinal symptoms & health-related quality of life among
           women with HR+/HER2– advanced or metastatic breast cancer treated in
           real-world settings in Italy and Germany
    • Authors: Brucker S; Law E, Ajmera M, et al.
      Abstract: Background: Gastrointestinal (GI) symptoms, including diarrhea and vomiting, are often reported by patients with advanced or metastatic breast cancer (ABC/mBC) and may affect patient care experience, health-related quality of life (HRQoL), and subsequent treatment decisions. This study characterizes the prevalence of GI symptoms and HRQoL among patients with HR+/HER2– ABC/mBC enrolled in the MARIA registry.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.022
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 10OComparison of patient populations identified by different PD-L1 assays
           in in triple-negative breast cancer (TNBC)
    • Authors: Scott M; Scorer P, Barker C, et al.
      Abstract: Background: TNBC represents an unmet clinical need; the IMPassion 130 and KEYNOTE-086 trials have demonstrated efficacy of PD-1/PD-L1 targeted therapeutics in the metastatic/unresectable first line setting, with increased response in PD-L1 high populations, defined using different diagnostic assays and algorithms. This work addresses the need to establish PD-L1 assay concordance in TNBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 101P_PRBreast cancer in young women: A multi-center 10-year experience
    • Authors: Eiriz I; Pereira N, Neves M, et al.
      Abstract: Background: Breast cancer is the most frequent cancer diagnosed in adult young women in Europe. Although rare (<5% before 35 years), it is one of the leading causes of death in this age group. The aim of this study is to characterize a cohort of young women regarding incidence, tumor stage, biology, treatment and survival.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.015
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 33PGermline PALB2 heterozygous mutations in breast cancers:
           Haploinsufficiency paradigm
    • Authors: Ouyang Q; Hu Z, Liu L, et al.
      Abstract: Background: PALB2 loss-of-function (Lof) mutation strongly suggests it as a tumor suppressor in familial breast cancer (BC). In Knudson’s hypothesis, mutation in both alleles is required for a single functional tumor suppressor to sufficiently cause malignant phenotype. But, some reports suggest the inhibition of one copy of PALB2 can lead to malignant phenotype (haploinsufficiency).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.032
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 56PHER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC)
           mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated
           breast cancer (BC) cell lines
    • Authors: Collins D; Gaynor N, Conlon N, et al.
      Abstract: Background: The monoclonal antibody (mAb) therapies trastuzumab (T) and pertuzumab (P) are used to treat the ∼20% of BCs classed as HER2-positive (+). The major modes of action of the mAbs are abrogation of HER2-mediated intracellular signaling, and engagement of immune cells through ADCC. The HER-family targeting TKIs lapatinib (LAP) and neratinib (NER) are approved for the treatment of HER2+ BC. LAP and NER can alter the expression of HER2 and the ADCC response to mAbs in vitro. This in vitro study examines the impact of the TKIs on the levels of HER2, MHC CLASS I, mAb binding and NK cell-mediated ADCC in BC cell line models.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.055
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 212PPatient-reported health problems and health care use after treatment
           for early breast cancer
    • Authors: de Ligt K; Heins M, Verloop J, et al.
      Abstract: Background: Insight in late treatment-related health problems following from breast cancer treatment is useful in anticipating on the (informational) needs of patients during follow-up. This study aimed to identify treatment-related health problems in breast cancer patients up to five years after diagnosis. Second, use of care associated to these health problems was identified.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 170PReal world patterns of use and value of pertuzumab in the treatment of
           HER2+ metastatic breast cancer in Singapore: The National Cancer Centre
           Singapore experience
    • Authors: Rahardja S; Tan R, Sultana R, et al.
      Abstract: Background: There are currently few reports on the pattern of use and value of Pertuzumab in the real-world setting. Our study describes the clinical efficacy and treatment costs of Pertuzumab in HER2-positive metastatic breast cancer (MBC) treated in a tertiary cancer centre in Singapore.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.021
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical
           trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients
           with triple negative breast cancer (TNBC) followed by adjuvant
           atezolizumab or placebo
    • Authors: Loibl S; Jackisch C, Rastogi P, et al.
      Abstract: Background: In TNBC neoadjuvant chemotherapy (NACT) is associated with increased pathological complete response (pCR). Thus, patients with a pCR have a favourable prognosis. However, patients with residual disease have a substantially increased risk of recurrence compared to those with other subtypes of breast cancer (Liedtke 2008, Loibl 2017). Blockade of PD-L1 binding by atezolizumab has resulted in relevant anti-tumor efficacy (Adams 2017, Schmid 2017).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 146PExpression of immunomodulatory molecule, programmed death ligand-1 in
           triple negative invasive breast cancer in the Indian population
    • Authors: Gorijavolu N; Augustine P, Subhadra Devi L, et al.
      Abstract: Background: Triple negative breast cancer (TNBC) account for about 30% of invasive breast cancers in the Indian population. TNBC is an inherently aggressive cancer with limited treatment options. Hence alternative lines of treatment are the urgent need of the day. Immune checkpoint inhibitors are a new class of drugs used in the treatment of various cancers, the advantage being long lasting response and reduced toxicity.PDL-1 is a ligand which is a part of this immunomodulating pathway.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz099.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 190PNon-vigorous physical activity and the risk of breast cancer among
           Nigerian women
    • Authors: Azubuike S; Hayes L, McNally R.
      Abstract: Background: Breast cancer incidence in Nigeria has risen by > 120% since 2000. Its mortality rate (18.8 / 100 000 women / year) ranks highest in Africa. Studies have suggested that non-vigorous physical activity is associated with reduced risk of breast cancer. However, its role in breast cancer risk is yet to be established in sub-Saharan Africa. Increasing prevalence of behaviours associated with reduced non-vigorous physical activity has been reported across several countries in sub-Saharan Africa, including Nigeria. The purpose of this study was to investigate if there is an association between non-vigorous physical activity and breast cancer risk among Nigerian women.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.041
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 77PHep par 1 immunohistochemistry in glycogen-rich clear cell carcinoma of
           the breast
    • Authors: Chang M; Wu J, Bethune G.
      Abstract: Background: Glycogen-rich clear cell carcinoma of the breast (GRCCC) is an uncommon variant of invasive breast cancer with abundant tumor-cell glycogen and thought to have poor outcome. There are conflicting reports on the prognosis of GRCCC and its pathologic/diagnostic criteria. Some features overlap with carcinomas having hepatoid features. We hypothesize that immunomarkers of hepatic differentiation may help distinguish GRCCC from more common breast cancers.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.073
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 55PTryptophan catabolism differentiates breast cancer patients from
           healthy controls but does not predict outcome
    • Authors: Onesti C; Boemer F, Josse C, et al.
      Abstract: Background: Indoleamine 2,3 dioxygenase (IDO) catalyzes the conversion of tryptophan (Trp) into kynurenine (Kyn), an immunosuppressive metabolite involved in T regulatory cell differentiation. IDO is expressed in many cancer types, including breast cancer (BC), but its association with prognosis is controversial. Here we analyze Kyn/Trp ratio, known as a surrogate indicator of IDO activity, in BC patients and in healthy control (CTRL).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.054
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 100PImproved survival of young patients with breast cancer ≤ 40
           years of age at diagnosis
    • Authors: Dick J; Khalil L, Charafeddine M, et al.
      Abstract: Background: Breast cancer in young women is generally considered to carry a worse prognosis. 50% of our patients (pts) are below the age of 50. We looked at our young patients age <40 years (y) with breast cancer at the American University of Beirut, assessed stages, characteristics and outcome.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 169PImpact of BRCA1/2 mutations status on patient reported outcomes in
           HER2- advanced breast cancer: Results from a multi-country real-world
           study
    • Authors: Rider A; Quek R, Lewis K, et al.
      Abstract: Background: Limited information is available on the effect of BRCA1/2 mutations on patient reported outcomes (PROs). This multi-country study assesses the impact of BRCA1/2 mutation status on patient demographics, cancer-related and breast cancer specific PROs in women with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.020
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 32PMicroRNA in combination with HER2-targeting drugs reduces breast cancer
           cell viability in vitro
    • Authors: Svartdal L; Aure M, Leivonen S, et al.
      Abstract: Background: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer is an aggressive cancer form due to regulation and initiation of intracellular signaling pathways that promote cell survival and proliferation. Although HER2-targeted therapy, like trastuzumab and lapatinib, has improved outcome for HER2+ breast cancer patients, not all patients respond to treatment. We hypothesize that HER2+ breast cancer cells with poor response to targeted treatment can be sensitized by combining microRNAs (miRNAs) with traditional targeted therapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.031
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 9OPara-necrotic expression of VEGFA metagene signature identified by
           single-cell profiling
    • Authors: Karn T; Denkert C, Weber K, et al.
      Abstract: Background: We previously identified a VEGFA metagene in TNBC which is associated with poor prognosis and eliminates the good prognostic effect of TILs (PMID 21978456, 28750120). But high pretreatment values of this signature predicted pCR in the neoadjuvant GeparQuinto trial (OR 2.40, P = 0.006) showing an interaction with bevacizumab treatment (P = 0.020). The main cellular sources of the transcripts that comprise the VEGFA metagene are unknown since mRNA profiling of bulk biopsies contains signals from different cell types. The individual genes have been reported to be expressed both in endothelial cells, fibroblasts, and epithelial cancer cells.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 211PA cost-utility analysis of administration schedules of G-CSF for
           primary prophylaxis of chemotherapy-induced febrile neutropenia in early
           stage breast cancer: Economic evaluation alongside the REaCT-G trial
    • Authors: Basulaiman B; Awan A, Hilton J, et al.
      Abstract: Background: Febrile neutropenia (FN) during adjuvant chemotherapy is associated with morbidity, mortality risk, and substantial cost. The optimal duration of filgrastim as primary FN prophylaxis in early stage breast cancer (EBC) patients is unknown. We compared the cost-effectiveness of 5, 7 or 10 days of filgrastim offered for primary FN prophylaxis.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 145PImmune functions of follicular helper CD4+CXCR5+ T cells in human
           breast cancer
    • Authors: Langouo Fontsa M; Noel G, Garaud S, et al.
      Abstract: Background: Tumor-infiltrating lymphocytes (TIL) have been associated with good clinical outcomes in HER2-positive (HER2+) and triple-negative (TN) breast cancer (BC) patients. Recently, we found that in 60% of BC, TIL are organized in tertiary lymphoid structures (TLS) in the stroma. We further identified a CXCL13-producing CD4+T follicular helper (Tfh) cell subpopulation associated with positive clinical outcomes in BC. We aimed to investigate how CD4+ Tfh cells, expressing the CXCL13 receptor CXCR5, contribute to immune response in BC TLS.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz099.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 189PBone seeking matrix metalloproteinase-2 (MMP-2) inhibitors can prevent
           bone metastatic breast cancer
    • Authors: Tauro M; Lynch C.
      Abstract: Background: Breast to bone metastasis is a common event during breast cancer progression. The resultant lesions are painful and currently, despite medical advances, are incurable. Therefore, identifying the underpinning molecular mechanisms in the bone microenvironment is vital for the development of new therapies. Gene expression analysis and validation in human and murine specimens of bone metastases revealed matrix metalloproteinases, such as MMP-2, are highly expressed in the bone metastatic microenvironment. These data support the rationale for the development of a highly specific MMP-2 inhibitor for the eradication of active bone metastatic breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.040
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 121TiPKEYNOTE-756: Randomized, double-blind, phase III study of
           pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant
           endocrine therapy (ET) for high-risk, early-stage estrogen
           receptor–positive human epidermal growth factor receptor 2–negative
           (ER+/HER2−) breast cancer (BC)
    • Authors: Cardoso F; Jia L, Hirshfield K, et al.
      Abstract: Background: Although ER+/HER2− BC has better overall prognosis than other subtypes, a high-risk subpopulation is characterized by high-grade tumors, decreased sensitivity to ET, higher responsiveness to CT, and worse prognosis. A meta-analysis of prospective studies on neoadjuvant chemotherapy (NAC) to treat stage I to III BC showed that increased pathologic complete response (pCR) rates at surgery were associated with improved survival in triple-negative BC, HER2+ BC, and high-grade HR+/HER2− BC. Patients with vs without pCR after NAC for high-grade HR+/HER2− BC had a 90% vs 60% 5-year event-free survival (EFS) rate, respectively. Thus, increased pCR rates after NAC may have a substantial impact on the survival of patients with high-risk, early-stage HR+/HER2− BC. KEYNOTE-756 (ClinicalTrials.gov, NCT03725059) is a global, randomized, double-blind, phase 3 study of pembrolizumab (pembro; vs placebo) + NAC followed by pembro (vs placebo) plus ET as adjuvant treatment for patients with high-risk, early-stage ER+/HER2− BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 76PPrognostic and predictive significance of the expression of the beta-2
           adrenergic receptor in HER2-positive breast cancer
    • Authors: Richard F; Bitton R, Sotiriou C, et al.
      Abstract: Background: The beta-2 adrenergic receptor (ADRB2) drives tumor proliferation and induces treatment resistance in preclinical models of HER2+ breast cancer. This study aimed to evaluate the predictive and prognostic role of ADRB2 expression as a biomarker in HER2+ breast cancer patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.072
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 99PTalking about risk in the context of genomic tests (TARGET): Evaluation
           of an educational program
    • Authors: Jenkin V; Fallowfield L.
      Abstract: Background: Decision-making about adjuvant chemotherapy in node neg, ER+, HER2- EBC requires balancing likely absolute benefits with treatment-related side effects. Health literacy and numeracy in general populations are often poor and many clinicians find explaining risk and uncertainty challenging especially when set against a backdrop of fear and anxiety. We developed and evaluated an educational program to aid discussions about gene expression profiling test (GEP) results from OncotypeDx and EndoPredict.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 54PPrognostic and predictive value of phosphorylated HER2, HER3 and PTEN
           expression in patients with HER2-positive breast cancer treated with
           trastuzumab
    • Authors: Debska-Szmich S; Kusinska R, Krakowska M, et al.
      Abstract: Background: Trastuzumab improves survival in HER2-positive breast cancer patients. But there are no other predictive markers for the treatment and only half of patients benefit from it. Our aim is to evaluate an association between expression of proteins engaged into HER2-signaling pathway and overall survival of patients treated with trastuzumab.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.053
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 31PThe spatial relations among immune cells are prognostic in inflammatory
           breast cancer
    • Authors: Van Berckelaer C; Colpaert C, Rypens C, et al.
      Abstract: Background: The mechanisms contributing to the aggressive biology of inflammatory breast cancer (IBC) are still under investigation. Our lab reported a 79-gene signature that is shaped by specific immune response programs and discriminates between IBC and non-IBC (nIBC). In this study we assessed the spatial associations between immune cells in IBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.030
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 168PAssociation of serum IGF1 and adiponectin in prognosis of breast
           cancer metastasis
    • Authors: Akter S; Faruque M, Nahar K.
      Abstract: Background: The WHO report revealed that breast cancer (BC) topped the list among various types of cancers in women in Bangladesh. The prognosis of metastatic breast cancer depends on certain factors, like surgery, radiotherapy, chemotherapy, hormonal receptor content of the tumor or associated illness such as diabetes mellitus and obesity. Among the associated illness, diabetes mellitus is one of the most common metabolic disease worldwide, which is linked to an increased risk of developing breast cancer and an even higher risk of recurrence and dying from this disease. In this context, we studied diabetic and metabolic disease related growth and metabolic factors in breast cancer patients for the better prognosis of BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.019
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 210PComparison of breast cancer outcomes in a private hospital with
           national outcomes in a country with a mixed public/private healthcare
           model
    • Authors: Killian M; Walsh P, Connor D, et al.
      Abstract: Background: Ireland has a mixed model of healthcare delivery with a public healthcare system funded by general taxation and a large private healthcare insurance system, covering 43% of the population in 2012 and 2016. We set out to examine disparities in outcomes among patients with breast cancer treated in a private hospital compared to national outcomes over a comparable period.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 123OVariation in radiotherapy after breast conserving surgery in patients
           aged 75 years or older between hospitals is not reflected in the
           locoregional recurrence risk
    • Authors: de Boer A; de Glas N, Marang-van de Mheen P, et al.
      Abstract: Background: Breast conserving surgery (BCS) followed by radiotherapy is the standard treatment for early stage breast cancer. As a result of uncertainty about the absolute benefit of radiotherapy in older patients, there is variation in the proportion of patients receiving radiotherapy after BCS. In this study, we assessed the variation between hospitals in the Netherlands among patients aged 75 years or older and evaluated its impact on locoregional recurrence risk.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 188PEfficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast
           cancer (BC) with brain metastases (BM): A single institution experience
    • Authors: Martin Huertas R; Lopez Miranda E, Corral de la Fuente E, et al.
      Abstract: Background: BM in HER2-positive BC patients are increasing, without agreement on the appropriate treatment of this subgroup. The disrupted blood-brain barrier in the setting of BM may allow the penetrance of T-DM1, with little evidence of its efficacy in this situation.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.039
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 8OThe mutational profile of IBC reveals higher mutational burden,
           deficiency of homologous recombination and NOTCH signalling
    • Authors: Van Laere S; Finetti P, Rypens C, et al.
      Abstract: Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with elevated metastatic potential. In the past, we have identified a gene expression profile that characterizes IBC, suggesting that a specific molecular biology underpins this devastating disease. Here, we explore the genomic alterations underlying IBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 167PUtilization and outcomes of Eribulin Mesylate POst a cyclin-dependent
           kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in
           UnitEd States community oncology pRactices (EMPOWER)
    • Authors: Mougalian S; Wang E, Alexis K, et al.
      Abstract: Background: As CDK 4/6i therapy becomes the standard of care in the early-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (mBC), this study evaluated the safety and effectiveness of eribulin mesylate when used post-CDK 4/6i treatment.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.018
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 120PPathological complete response in early breast cancer patients
           undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes
           
    • Authors: Rapoport B; Barnard-Tidy J, Van Eeden R, et al.
      Abstract: Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) has been proposed as a surrogate endpoint for of long-term clinical benefit, such as disease-free survival, event-free survival, and overall survival in patients (pts) with early breast cancer (BC). The association between molecular subtypes, clinicopathological features, and pCR rate in early BC pts treated with NAC were examined.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 98PAdjuvant management of male breast cancer in Bulgaria
    • Authors: Konsoulova-Kirova A; Yordanov A, Kostova-Lefterova D, et al.
      Abstract: Background: As a rare disease, knowledge about management of male breast cancer (male BC) is scarce but increasing in the last years. Still, according to RARECAREnet study, 5-year relative survival in Bulgarian male BC patients is 18% less than European mean. We look for potential reasons for this low survival rate; we also identify trends or gaps in the adjuvant (ADJ) management. Analysis of available data would lead to perception of the lack of knowledge about management of MBC and would identify areas for future improvement.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 53PActivity of chemotherapy drugs in patient-derived xenografts (PDXs)
           from chemotherapy naïve local-regional triple negative breast cancer
           (LR-TNBC) patients
    • Authors: Martín M; Ramos-Medina R, Garcia Sáenz J, et al.
      Abstract: Background: LR-TNBC is responsive to polychemotherapy regimens including anthracyclines, taxanes and, more recently, carboplatin. However, we are ignorant of the individual contribution of each of these agents to the global activity of the combinations. Identifying single drug activity in the clinical setting is challenging. We used instead PDXs from LR-TNBC to test single chemotherapy drugs and combinations.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.052
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 30PUpdate on the phase II SUMMIT trial: Neratinib + fulvestrant for
           HER2-mutant, HR-positive, metastatic breast cancer
    • Authors: Smyth L; Saura C, Piha-Paul S, et al.
      Abstract: Background: Somatic mutations in HER2 (ERBB2) are oncogenic and may confer resistance to endocrine therapy in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has single-agent clinical activity in HER2mutant MBC and is synergistic with fulvestrant in preclinical studies. In SUMMIT (NCT01953926), a phase 2 basket trial of neratinib in HER2-mutant solid tumors, the HR+ MBC cohort had encouraging outcomes with neratinib plus fulvestrant (N+F) [Oct 2018 datacut; Smyth et al. SABCS 2018; #PD3-06]. Updated results from this cohort will be reported, detailing the impact of prior therapies on clinical efficacy of N+F in HER2-mutant HR+ MBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.029
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 209PCompromised cancer-specific survival among under-insured Chinese
           patients with breast cancer: A prospective cohort study
    • Authors: Xie Y; Valdimarsdóttir U, Gou Q, et al.
      Abstract: Background: Little is known about whether health insurance policies, particularly in developing countries, influence breast cancer prognosis. We aimed to examine the association between individual health insurance coverage plan among patients with invasive breast cancer in China and risks of breast cancer-specific mortality.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 74PInflammatory breast cancer cells are characterized by abrogated
           TGFβ1-dependent cell motility and SMAD3 activity
    • Authors: Rypens C; Van Berckelaer C, Billiet C, et al.
      Abstract: Background: Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer with elevated metastatic potential, characterized by the frequent presence of tumor emboli in dermal and parenchymal lymph vessels. This study examines the role of TGFβ signaling in the molecular biology of IBC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.071
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 187PSensitivity and dynamic range of CellSearch based CSF DTC enumeration
           in patients with breast cancer related leptomeningeal metastases (LM)
    • Authors: Van Goethem A; Rypens C, Rutten A, et al.
      Abstract: Background: Improvements in the systemic treatment of patients with metastatic breast cancer (MBC) and the inefficiency of many drugs in crossing the blood brain barrier have led to an increased incidence of symptomatic CNS metastasis. CNS metastases are clinically characterized by two distinct phenotypes, solid CNS metastasis and leptomeningeal metastases (LM). In addition to its poor prognosis, neurological impairment in LM is devastating. No major advances have been made in the treatment and diagnosis of LM, which remains challenging due to low sensitivity of CSF cytology and/or unequivocal MRI findings.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.038
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine
           therapy (ET) in HR+/HER2– advanced breast cancer (ABC)
    • Authors: Tripathy D; Hortobagyi G, Chan A, et al.
      Abstract: Background: RIB (cyclin-dependent kinase 4/6 inhibitor) + various ET partners demonstrated longer progression-free survival vs placebo (PBO) + ET in patients (pts) with HR+/HER2– ABC in the Phase III MONALEESA (ML) studies. Here we present a safety analysis of pooled data from ML-2, ML-3, and ML-7.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.017
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 143PA systemic review of information requirements of young women with
           breast cancer undergoing mastectomy or breast conserving surgery
    • Authors: Mehmood T.
      Abstract: Background: Young women with breast cancer have poorer prognosis, greater lifetime risk of local recurrence, contralateral recurrence, and distant disease, regardless of surgery received. Here we systematically review published evidence relating to the information requirements and preferences of young women diagnosed with early-stage breast cancer offered a choice between mastectomy and breast conservation surgery (BCS). Findings will inform the development of a surgical decision aid for young women.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.020
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 119PA systematic review of endocrine deprivation therapy administered in
           the neoadjuvant setting in double positive breast cancer
    • Authors: Smith M; Doran P, Kelly C, et al.
      Abstract: Background: Breast cancer is the most common tumour diagnosed in women worldwide and is the second leading cause of cancer death. The use of trastuzumab or Herceptin®, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) together with chemotherapy has changed the natural history of breast cancers overexpressing HER2. There is mounting evidence that responses differ according to hormone receptor (HR) status. The behaviour of so called “double positive” tumours and how they respond to existing therapies are relevant clinical questions. Late recurrences and risk of death is characteristic of this subtype. HER2 is overexpressed in 25% of all breast cancers. In nearly 50% of these there is co-existence of oestrogen receptor (ER) and progesterone (PgR) expression. Neoadjuvant treatment combining chemotherapy and trastuzumab is standard of care. Pathological complete response (pCR) rates are consistently inferior in HER2 positive patients who are ER positive compared to those with ER negative disease. This review addresses the role for adding endocrine deprivation therapy (EDT) in the neoadjuvant setting.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 52PThe early changes of ΔSUV is a predictive marker of response and
           outcome in everolimus treated patients with mBC
    • Authors: Sirico M.
      Abstract: Background:18F-FDG PET/CT is regarded as one of the essential imaging for establish the efficacy of breast cancer therapy and the measures of tumor burden showed promises to predict OS in patients with mBC. Everolimus leads to decreased protein synthesis, cell metabolism and cell proliferation in solid tumors. Identification of predictive markers for everolimus-based treatment remains a major issue, but to date, no predictive markers have been established. The aim of this study is to evaluate an optimal ΔSUV% [(SUV baseline-SUV 3 months)/SUV baseline] as a predictive factor of OR and DFS in patients with mBC cancer receiving everolimus and exemestane in 1^ line treatment.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.051
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 97PAdjuvant trastuzumab in stage I breast cancer with the tumour size <
           1 cm: Our centre experience
    • Authors: Belikova H; Alhasso A.
      Abstract: Background: Small node-negative breast cancers measuring less than 1 cm are generally associated with a favorable prognosis. Around 10% of these malignances exhibit human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. Patients with HER2+ tumors have a higher risk of recurrence. Several large retrospective reviews have reported a lower overall survival among HER2+ cases in the pT1a/b N0 patient group where adjuvant treatment was not given. In this retrospective study we looked at our institutional experience of using trastuzumab (Herceptin®) in early breast cancer, and how the outcomes compared to the same stage of HER2+ group not treated with Herceptin®, or HER2- group.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 29PHeterozygous mutation in fanconi anemia genes associated with
           hereditary breast cancer
    • Authors: Gordiev M; Brovkina O, Shigapova L, et al.
      Abstract: Background: Defects in DNA damage recognition and repair has been implicated in hereditary breast cancer (BC). Several studies demonstrated, that Fanconi Anemia (FA) associated genes-coding proteins and products of BRCA1/2 genes cooperate in a DNA repair pathway which is required for resistance to DNA interstrand crosslinks. Our aim was to analyze nucleotide variants in FA genes predisposing with an increased risk of hereditary cancers.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.028
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 208PSecond malignancies with breast cancer: An audit
    • Authors: Srinivasalu V; Subramaniam N, K S S, et al.
      Abstract: Background: Breast cancer survivors are at a higher risk of getting another breast cancer, as well as some other types of cancer. The most common second cancer is another breast cancer either at the same side or on the opposite side. Various factors are implicated in increasing the risk of second primary like hormonal therapy, radiation to the breast and axilla and chemotherapy. We aimed to asses the risk of second cancers in breast cancer survivors.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 7OPAM50MET: A prognostic model based on PAM50 and clinical variables in
           metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
    • Authors: Prat A; Tsai Y, Pascual T, et al.
      Abstract: Background: Predicting prognosis in metastatic HR+/HER2-negative disease might be of clinical value. Here, we developed and validated a prognostic biomarker in 765 patients (pts) recruited in 2 phase III trials evaluating endocrine-based therapies.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 165PPrevalence of risk factors for QT prolongation and torsades de pointes
           among women with HR+/HER2– advanced or metastatic breast cancer treated
           in real-world settings in Italy and Germany
    • Authors: Harbeck N; Law E, Ajmera M, et al.
      Abstract: Background: Several cancer treatments available for patients with HR+/HER2- advanced or metastatic breast cancer (ABC/MBC) may be associated with prolonged corrected QT interval (QTc), which may increase the risk of life-threatening ventricular arrhythmias, such as Torsades de Pointes (TdP). Therefore, identifying risk factors for QTc prolongation is imperative to ensuring safe and effective therapy tailored to individual patients. This interim analysis characterizes QTc/TdP risk among women with HR+/HER2- MBC living in Italy and Germany included in the MARIA registry.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.016
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 142PRelapse after radical subcutaneous mastectomy with simultaneous
           reconstruction in patients with breast cancer
    • Authors: Rasskazova E; Zikiryakhodzhaev A, Khakimova S.
      Abstract: Background: To evaluate relapses in patients with breast cancer (BC) who underwent radical subcutaneous mastectomy with simultaneous reconstruction.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.019
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 186PHER2-positive breast cancer and CNS metastases: Prognostic factors and
           clinical outcome
    • Authors: Agostinetto E; Masci G, Giordano L, et al.
      Abstract: Background: Since the introduction of trastuzumab-containing therapies, patients (pts) with HER2-positive breast cancers (BC) are experiencing longer progression-free (PFS) and overall survival (OS). However, the extending life expectancy of these pts is associated with an increased incidence of distance recurrences and, particularly, central nervous system (CNS) metastases. Aim of this study is the evaluation of factors which could affect prognosis from diagnosis of CNS metastatic disease to death.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.037
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 72PClinico-pathological relationship between androgen receptor (AR) and
           tumor infiltrating lymphocytes (TILs) in triple negative breast cancer
           (TNBC)
    • Authors: Elghazawy H; Alorabi M, Helal T, et al.
      Abstract: Background: Triple negative breast cancer (TNBC) is an aggressive subtype of with ill-defined therapeutic targets. Androgen receptor (AR) expression ranged from 32-53% in different reports presenting emerging biomarker in TNBC. Tumor-infiltrating lymphocytes (TIL) play an important prognostic and predictive value in TNBC. The relationship between AR, TIL and clinical behavior is still not fully understood.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.070
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 28PImpact of the 21-gene assay on treatment decisions in high-risk
           patients with ER-positive HER2-negative early breast cancer: Results of
           the KARMA Dx study
    • Authors: Llombart A; Andrés R, Anton Torres A, et al.
      Abstract: Background: Patients (pts) with ER+, HER2– early breast cancer (EBC) do not universally benefit from adding adjuvant chemotherapy (CT) to hormonal treatment (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay is uniquely designed and validated to guide CT treatment decisions in this population.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.027
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 118PDose dense neoadjuvant and adjuvant chemotherapy in triple-negative
           breast cancer patients: Survival analysis
    • Authors: Kr A.
      Abstract: Background: Breast cancer is the most common cancer in Indian women. Triple negative breast cancer (TNBC) is associated with poor prognosis at any stage of diagnosis. It is an aggressive disease with a 5-year survival rate of 77% compared to 93% for other subtypes. Prevalence of TNBC in India is higher compared to western populations, making it an important target for early detection and treatment. Potential superiority of dose-dense chemotherapy in comparison with conventional regimen has been recently demonstrated in a meta-analysis in 2017 across various subsets of breast cancer. Aim of this study was to analyse survival outcomes in TNBC treated with dose dense chemotherapy at a tertiary care centre in India.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 51PHigher ER load is not associated with better outcome in stage I-III
           breast cancer
    • Authors: Noordhoek I; de Groot A, Cohen D, et al.
      Abstract: Background: In breast cancer, hormone receptor (HR) status is generally a qualitative measure; either positive or negative. Quantitative measurement of HRs has often been proposed as a prognostic and predictive marker in breast cancer, some guidelines even provide different treatment options for patients with strong versus weak expression. We aimed to evaluate quantitative HR load assessed by immunohistochemistry (IHC) as a prognostic and predictive marker for patients with stage 1-3 breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.050
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 207PAfter breast cancer: A nurse practitioner led model of care for women
           on adjuvant endocrine treatment
    • Authors: Shenkier T; Lohrisch C, Simmons C, et al.
      Abstract: Background: In British Columbia (BC), women taking adjuvant endocrine therapy (AET) for early breast cancer are followed by their oncologist for a variable length of time before discharge to their family physician (FP). Many women have physical and psychological needs beyond the scope of their FPs or the capacity of their oncologists to follow longitudinally. In addition, non-adherence to AET occur in over 40% of patients and is associated with increased mortality (Hershman, D Breast Cancer Res Treat 2011). We postulated that establishment of a dedicated service to assess and address symptoms and signs experienced while taking AET could improve quality of life (QOL) and potentially improve adherence.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 164PLocoregional therapy targeted at the primary tumour improves overall
           survival in patients with stage IV metastatic breast cancer: A systematic
           review and meta-analysis with 185942 patients
    • Authors: Gera R; Mokbel K, El Hage Chehade H, et al.
      Abstract: Background: Metastatic breast cancer is a complex disease that is traditionally treated using systemic therapy. There is mounting evidence that locoregional therapy (LRT), such as resection of the primary tumour and/or localised radiotherapy could be associated with improvements in survival. We aimed to conduct a meta-analysis to inform decision making.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.015
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 96PAdjuvant radiotherapy induces secondary tumor events in breast cancer
           patients with Li-Fraumeni syndrome
    • Authors: Rounis K; Koukaki T, Christodoulou C, et al.
      Abstract: Background: Breast cancer (BrCa) patients with Li-Fraumeni Syndrome (LFS) require customized clinical care, mainly due to elevated lifetime cancer risks that these patients face, as well as the diagnosis of secondary, radio-induced neoplasms. Preclinical data have shown that TP53 deficient cells are at increased risk of malignant transformation in the setting of ionizing radiation. TP53 pathogenic variants are strongly associated with very early onset, frequently HER2-amplified BrCa diagnosis.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 6OUtility of early circulating tumour DNA dynamics as a surrogate for
           progression free survival in the BEECH phase I/II trial in metastatic
           breast cancer
    • Authors: Hrebien S; Citi V, Garcia-Murillas I, et al.
      Abstract: Background: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome of therapy. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression free survival (PFS) and early predictor of drug efficacy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 185PClinical, biological and histological features predictive of response
           to everolimus in metastatic breast cancer patients
    • Authors: Van den bossche V; Jadot G, Augusto D, et al.
      Abstract: Background: The PI3K/Akt/mTOR pathway is frequently activated in breast cancer (BC) and is implicated in resistance to endocrine therapy (ET). Addition of everolimus (EVE), an mTOR inhibitor, to ET improves cancer control compared to ET alone. However, in previous studies, the median progression-free survival (PFS) did not exceed 7 months (mo), responses were inconsistent and there was no efficient predictive biomarker of efficacy. We aimed to define a correlation between clinical, biological or histological features and EVE efficacy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.036
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 141PImplant-based breast cancer reconstruction with biological matric or
           synthetic mesh
    • Authors: Sukhotko A; Zikiryahodjaev A, Ermoshchenkova M, et al.
      Abstract: Background: In recent years, considerable success has been achieved in complex and combined treatment of breast cancer (BC). Reconstructive plastic surgery plays an important role in the rehabilitation of patients with breast cancer and it is currently considered as the causal treatment of mental disorders caused by loss of femininity and integrity of one’s own body. One-step breast reconstruction for cancer treatment makes it possible to use supplementary materials – synthetic and biological implants that can replace muscle autografts and thereby reduce trauma, blood loss, operation time, they help to avoid the defect of donor areas. The authors describe the state of the art at present and demonstrate the results of their own research.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.018
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 50PER pathway activity score as a predictive biomarker to improve
           stratification for neoadjuvant endocrine therapy
    • Authors: Keizer D; Inda M, Clout D, et al.
      Abstract: Background: Endocrine therapy for breast cancer patients is currently determined based on positive estrogen receptor alpha (ER) staining measured by immunohistochemistry. However, not all selected patients will respond to this therapy, suggesting that ER staining is not an optimal predictor for therapy response. We previously described a new method to measure functional signal transduction pathways based on a Bayesian inference from measurements of mRNA levels (microarray, qPCR) of the specific ER pathway related target genes. Initial evaluation suggested that ER pathway activity score of the primary biopsy is related to clinical response. In this study, this association is confirmed together with the observation that only the ER pathway activity is targeted by endocrine therapy, making this pathway activity score a possible candidate for response prediction to this therapy.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.049
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 27PBiological features of estrogen receptor-positive breast cancer with
           elevated RANK (TNFRSF11A) expression
    • Authors: Casimiro S; Gomes I, Almeida B, et al.
      Abstract: Background: The receptor activator of NFkB (RANK)-RANK ligand (RANKL) pathway, pivotal regulator of bone remodeling, has emerged as a major mediator of progesterone-driven breast cancer (BC) carcinogenesis. RANK expression is particularly elevated in triple negative BC and has been associated with aggressiveness and poor prognosis. This study addressed the impact of elevated RANK expression in estrogen receptor (ER)-positive BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.026
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 206PProtroca: A non-interventional study on prophylaxis of chemotherapy
           induced neutropenia using lipegfilgrastim in non-selected breast cancer
           patients
    • Authors: Wuerstlein R; Harbeck N, Grischke E, et al.
      Abstract: Background: WSG (West German Study Group)-Protroca evaluated the efficacy and safety of primary and secondary prophylaxis (ppx) of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer (BC) patients (pts) receiving neo-adjuvant or adjuvant treatment in routine praxis.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 117PThe prognostic and predictive role of the androgen receptor in TNBC
           treated with neo-adjuvant chemotherapy
    • Authors: Jongen L; Floris G, Laenen A, et al.
      Abstract: Background: The prognostic and predictive value of the androgen receptor (AR) in triple negative breast cancers (TNBC) remains controversial. We assessed the impact of AR in TNBC on core needle biopsy (CNB) and remaining tissue after neo-adjuvant chemotherapy (NACT) by menopausal status which affects the androgen/estrogens relation and pathological complete response (pCR) rate.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 163PSAKK 21/12: A stratified, multicenter phase II trial of transdermal
           CR1447 in endocrine responsive-HER2 negative and triple negative-androgen
           receptor positive metastatic or locally advanced breast cancer
    • Authors: Vetter M; Rothgiesser K, Li Q, et al.
      Abstract: Background: CR1447 is a novel transdermal formulation of 4-OH-Testosterone with aromatase inhibiting properties and androgen receptor modulation. Phase I data demonstrated efficacy and a favorable toxicity profile. In this trial efficacy and toxicity cohort A (A) with estrogen-receptor positive disease and cohort B (B) with androgen-receptor positive triple negative metastatic breast cancer was investigated.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 70PLong non-coding RNA PART1 contributes to cell proliferation and stem
           cell maintenance in triple-negative breast cancer
    • Authors: Cruickshank B; Vidovic D, Dahn M, et al.
      Abstract: Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking targeted therapy options. Novel therapies which also target chemotherapy-resistant cancer stem cells (CSCs) within tumors would lead to improved outcomes for TNBC patients. Breast CSCs can be defined by increased aldehyde dehydrogenase (ALDH) enzymatic activity. Recent evidence suggests that long non-coding RNAs (lncRNAs) contribute to CSC maintenance and are potential novel therapeutic targets.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.069
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 184PCAM-H2 effectively targets and treats HER2 positive brain lesions: A
           comparative preclinical study with trastuzumab
    • Authors: Puttemans J; D’Huyvetter M, Windhorst B, et al.
      Abstract: Background: Despite extensive research in systemic treatments for HER2 positive breast cancer brain metastases (BCBM), only limited benefits have been observed often at the cost of significant toxicities. Treatment failure is attributed to the limited capacity of drugs to cross the blood-tumor-barrier (BTB) or to resistance mechanisms in the brain lesion microenvironment. In this study we evaluate the radiolabeled drug CAM-H2 as a new systemic treatment for the irradiation of HER2 positive BCBM. Single domain antibody fragments (sdAbs) are small (15 kDa) heavy-chain-only antibody fragments. Due to their favorable pharmacokinetics, sdAbs are tested as targeting vehicles for the delivery of cytotoxic irradiation to cancer lesions inside and outside the brain. Here we measure the potential of CAM-H2 (131-Iodine conjugated anti-HER2 sdAb 2Rs15d) for targeting brain lesions with imaging and compare its therapeutic efficacy with Trastuzumab in a preclinical model.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.035
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 49PThe metastatic potential of grade I breast carcinoma of no special
           type: A deep insight into putative molecular mechanisms
    • Authors: Lessi F; Scopelliti C, Aretini P, et al.
      Abstract: Background: Metastasis continues to be a crucial problem for the clinical management and treatment of breast cancer (BC). Among breast carcinoma of no special type (BC-NST), grade 1 tumors do have the best prognosis in terms of recurrence and overall survival. However, rarely they metastasize to the axilla, suggesting a more aggressive behaviour. Our study aimed to uncover the mechanism responsible for the dissemination of tumor cells of grade 1 BC-NST into axillary lymph nodes in order to better understand lymph node metastasis phenomenon in BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.048
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 205PA prospective, multicentre, randomized trial comparing vascular access
           strategies for patients receiving non-trastuzumab containing chemotherapy
           for early stage breast cancer
    • Authors: Awan A; Basulaiman B, Robinson A, et al.
      Abstract: Background: Chemotherapy for patients with early stage breast cancer (EBC) can be administered through either a peripheral vein or a central line (i.e. PICC or PORT) associated with different risks, benefits and costs. As the optimal type of vascular access is unknown, the feasibility of using a novel pragmatic trial model with integrated oral consent model to compare peripheral with central access was performed.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.006
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 140PEvaluation of intraoperative frozen section with final histopathology
           results for sentinel lymph node biopsy in breast cancer
    • Authors: Kr A; Sp S, Kumar R.
      Abstract: Background: Intraoperative assessment of sentinel lymph nodes for patients undergoing surgery for early breast cancer has the potential to reduce the need for delayed axillary lymph node dissection (ALND), significantly reducing patient morbidity, expediting adjuvant therapy, reducing length of hospital stay and cost of hospitalisation. This study aims to evaluate intraoperative frozen section in identifying cancerous involvement of sentinel lymph nodes in early breast cancer.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.017
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 5OTILs in ER+/HER2- breast cancer
    • Authors: Criscitiello C; Vingiani A, Maisonneuve P, et al.
      Abstract: Background: The role of tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer (BC) is debated. We evaluated the association of TILs and clinico-pathological (CP) features with distant disease-free survival (DDFS) in a large series of patients (pts) with ER+/HER2- BC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 95PThe changing role of gene-expression profiling in the era of
           de-escalating adjuvant chemotherapy in early stage breast cancer
    • Authors: Steenhoven J; Kuijer A, Schreuder K, et al.
      Abstract: Background: There is a growing body of evidence supporting the omission of adjuvant chemotherapy in a subset of estrogen receptor (ER) positive (+) / Her2 receptor negative (-) breast cancer patients. We assessed recent trends in the administration of adjuvant chemotherapy thereby evaluating the role of the 70-gene signature (70-GS) testing in decision-making in the systemic treatment of lymph node negative (N0) and lymph node positive (N+) breast cancer patients.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.009
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 162PHospitalization and supportive care medication (SCM) utilisation in
           patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2
           mutation (gBRCAm) in EMBRACA
    • Authors: Ettl J; Quek R, Hurvitz S, et al.
      Abstract: Background: EMBRACA, a randomized 2:1 open-label Phase 3 trial (NCT01945775), showed a significant improvement in progression-free survival with talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) (HR = 0.54; 95%CI: 0.41,0.71; P<.0001) in pts with HER2-negative ABC and a gBRCAm. This analysis evaluated the hospitalization and SCM utilisation while accounting for TALA/PCT–treatment-emergent period in EMBRACA.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.013
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 26PUtilization and performance of the Prosigna® breast cancer prognostic
           gene signature assay at the Medical University of Vienna
    • Authors: Tendl K; Monschein L, Exner R, et al.
      Abstract: Background: The Prosigna breast cancer assay provides independent additional prognosic value compared to classic pathohistological and immunohistochemical (IHC) parameters and assists adjuvant therapy decisions. In the present study, we retrospectively evaluated correlation of Prosigna breast cancer assay intrinsic subtype (IST) with immunohistochemical (IHC) IST estimation in a clinical setting.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.025
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 183PCD146 suppresses breast tumor via its novel downstream signaling
           pathway, Latexin/Akt/NFκB
    • Authors: Ouhtit A; Fernando A.
      Abstract: Background: CD146 or Mel-CAM, a member of the immunoglobulin-like CAM family, is activated through a dimerization of its ligand, leading to a cascade of signal transduction events. While CD146 is a promoter of melanoma and prostate cancer, its role in BC remains nascent and controversial. However, we have recently reported that CD146, a negative transcriptional target of CD44-HA downstream signaling, suppresses breast tumor cell invasion; this has prompted us to generate the hypothesis that CD146 acts as a tumor suppressor in BC via its downstream transcriptional targets.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.034
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 48PHereditary breast and ovarian cancer syndrome: Descriptive analysis of
           a familial cancer clinic
    • Authors: Amaral S; Cunha Pereira T, Monteiro A, et al.
      Abstract: Background: Germline mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2 are associated with inherited predisposition for breast and ovarian cancer. Pattern of mutations varies considerably among different populations, and there are groups with high prevalence of particular mutations according to geographical area, as the c.156_157insAlu BRCA2 rearrangement, a founder mutation of Portuguese origin and one of the most frequent BRCA2 mutations described to date. In this study we review the clinical and pathological characteristics of the patients with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), the BRCA1 and BRCA2 mutation spectrum and evaluate its relation with clinical outcomes.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.047
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 139PRate of breast-conserving surgery vs mastectomy in developing
           countries
    • Authors: Kr A; Sp S, Kumar R.
      Abstract: Background: Worldwide, breast conservation has become increasingly accepted as the surgical management of breast cancer in clinical practice. Cancer care in India is also evolving tremendously with many cancer treatment centres following evidence-based practice hence the rates of breast conservation are expected to increase. Here, we are reporting the rate of breast-conserving surgery (BCS) at our centre.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.016
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 116PStudy of pathological complete response rates with neoadjuvant
           concurrent chemoradiation with paclitaxel in locally advanced breast
           cancer
    • Authors: Iyer P; Radhakrishnan V, Balasubramanian A, et al.
      Abstract: Background: Neoadjuvant concurrent chemoradiation (CTRT) is not widely practised in breast cancer. We present our experience with the use of neoadjuvant CTRT in patients with locally advanced breast cancers (LABC) treated at our centre.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 204PIncreased risk of breast cancer-specific mortality among women with
           second primary breast cancer: A SEER population-based study
    • Authors: Wang C; Hu K, Zheng H, et al.
      Abstract: Background: With largely improved cancer survivorship in past decades, cancer survivors developed second primary breast cancer (BCa-2) are not uncommon. However, little is known about the prognosis of BCa-2. We therefore aimed to examine the risk of breast cancer-specific mortality among patients with BCa-2 compared with those with first primary breast cancer (BCa-1).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.005
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 69PLong duration of breastfeeding is associated to inflammatory breast
           (IBC) cancer
    • Authors: Mejri N; El Benna H, Rachdi H, et al.
      Abstract: Background: We aimed to evaluate the role of breastfeeding as a risk factor of IBC compared to non-IBC and according to hormonal (HR) and human epidermal growth factors receptors (HER2) receptor status.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.068
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 161PBRCA status, treatment patterns and outcomes in HER2- advanced breast
           cancer (ABC): A multi-country real-world study
    • Authors: Niyazov A; Quek R, Lewis K, et al.
      Abstract: Background: BRCA testing rates, treatment patterns and outcomes were compared based on BRCA mutation status in HER2- adult women with ABC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.012
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 25PExpression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial:
           Comparison of central immunohistochemistry with an automated
           cartridge-based system for mRNA assessment (on behalf of the GBG
           neoadjuvant and translational subboard)
    • Authors: Denkert C; Jank P, Link T.
      Abstract: Background: Measurement of hormone receptors, HER2 and Ki-67 is prognostic for breast cancer (BC) outcome and prediction of therapy response. The Xpert® Breast Cancer STRAT4 based on RT-qPCR, is used to classify BC tissues regarding their hormone receptor status, HER2 and proliferation via Ki-67. This study compares the mRNA expression analysis of ER, PR, HER2, and Ki-67 in a large clinical trial cohort by an automated in-vitro diagnostic platform and central IHC.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.024
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 4ORelationship between tumor infiltrating lymphocytes (TILs) and response
           to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT)
           for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    • Authors: Loi S; Schmid P, Aktan G, et al.
      Abstract: Background: Higher stromal TILs (sTILs) are associated with higher pathologic complete response (pCR) rates with CT in early-stage TNBC. We evaluated the association between sTILs and PD-L1 expression with response to pembro+CT as NAT for TNBC in KEYNOTE-173 (NCT02622074).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.003
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 94PCholesterol-lowering medication: Impact on the clinical effect of
           adjuvant endocrine treatment in postmenopausal breast cancer
    • Authors: Harborg K; Heide-Jørgensen U, Ahern T, et al.
      Abstract: Background: Observational studies suggest that cholesterol-lowering medication (CLM) use is associated with longer recurrence-free survival in breast cancer patients. Since 2007, aromatase inhibitors (AIs) have been guideline treatment for estrogen receptor positive (ER+) postmenopausal breast cancer. AI therapy is associated with increased cholesterol levels. We investigated the association of CLM use and breast cancer recurrence rate in patients treated with AIs.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.008
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 182PEfficacy and tolerability of neratinib in advanced HER-2 positive
           breast cancer: A single institution experience
    • Authors: Shepherd S; Lee K, Mohammed K, et al.
      Abstract: Background: Neratinib is an oral small-molecule irreversible pan-HER tyrosine kinase inhibitor in late stage clinical development for advanced HER-2 positive breast cancer. Prophylactic loperamide (4mg qds Day 1, tds days 2-14, bd days 15-28 then prn) and budesonide (9mg od for 28 days) are required to reduce the incidence and severity of diarrhoea.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.033
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 203PThe analysis of statistics of breast cancer in Cherkassy region before
           and after Chernobyl disaster
    • Authors: Zrielykh L.
      Abstract: Background: Ionizing radiation can influence on cells of organisms through the chain of electric, physico-chemical, chemical and biological effects leading to different damages, genetic abnomalities and death. On 26 April 1986 the explosion of atomic reactor of the fourth power unit of Chernobyl Nuclear Power Station happened, having thrown into the atmosphere nearly 50 tons of nuclear fuel with the activity of 15-20 thousands of rentgen per hour. This disaster had detrimental outcome for people living in Ukraine and other countries, resulted to increase of morbidity and mortality from different diseases, especially oncological.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz101.004
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 47PPalbociclib-induced senescence upregulates the expression of IL-8 and
           may enhance the response to inmunotherapy
    • Authors: Martinez Bueno A; Bertran Aramillo J, Garcia Mosquera J, et al.
      Abstract: Background: Senescence is a well characterized effect of the CDK4-6 inhibitors, and senescent cells have been described to produce inflammatory mediators as part of a “senescence associated secretory phenotype (SASP)”. We hypothesized that CDK4/6 inhibitors, following cell cycle arrest and induction of senescence can increase the production of inflammatory mediators by breast cancer cells, such as IL-8, that are known to enhance the activity of anti-PD-L1 agents.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.046
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 138PEfficacy of using imprint and exfoliative cytology followed by frozen
           section as intraoperative margin assessment in breast conservation surgery
           
    • Authors: Tamanuki T; Namura M, Aoyagi T, et al.
      Abstract: Background: Intraoperative imprint and exfoliative cytology (IEC) or frozen section (FS) are margin assessment techniques to reduce reoperation risk. These techniques reduce the rate of positive margin on permanent section (PS) after breast conservation surgery (BCS), which lead to reduction of reoperation. The rate of positive margin using these techniques are reported accounts for 6–19% of BCS. However, previous studies reported only the single use of each method. The purpose of this study was to elucidate the efficacy of using IEC followed by FS as intraoperative margin assessment (IMA) in BCS regarding the positive margin rate of PS.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.015
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 3OComprehensive evaluation of methodology to assess abundance of immune
           infiltrates in breast cancer
    • Authors: Nederlof I; de Bortoli D, Bareche Y, et al.
      Abstract: Background: The immune system is critical in modulating therapeutic sensitivity and tumor progression in breast cancer patients. A plethora of methods exists to evaluate the amount and composition of tumor immune infiltrates and are used interchangeably, based on the assumption that they provide similar information. A systematic comparison of these methods, including microscopy evaluations and algorithms based on transcriptomic and methylation data, is still lacking.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.002
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 160PCDK 4/6 inhibitors plus endocrine therapy in ER positive metastatic
           breast cancer (MBC): Systematic review and meta-analysis of randomized
           clinical trials
    • Authors: D’Avanzo F; Saggia C, Rossi V, et al.
      Abstract: Background: CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have been rencently introduced in the clinical management of ER positive metastatic breast cancer (MBC) patients, based on significant improvements in terms of progression free survival (PFS); however, no improvent in overall survival (OS) has been demonstrated in individual trials so far. The purpose of this analysis was to assess, across trials, the effect on progression free (PFS) and overall survival (OS) of the combination of endocrine therapy and CDK 4/6 inhibitors.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.011
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 24PA nomogram integrating reverse phase protein array based proteomic
           signature and clinical variables improves prognostic prediction in
           non-metastatic breast cancer after surgery
    • Authors: Junping Y; Channan Q.
      Abstract: Background: Most studies have used genomic profiles to dissect the heterogeneity of breast cancer (BC) to improve clinical outcome, however, very few studies pay attention to protein profiles. Thus, we aimed to explore the prognostic value of reverse phase protein array (RPPA)-based proteins and integrated them into a nomogram with clinical variables to predict outcomes in non-metastatic BC after surgery.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.023
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 181PA nationwide, multi-institutional retrospective study of efficacy and
           safety of eribulin in Korean breast cancer patients (REMARK)
    • Authors: Jeong J; Park M, Lee S, et al.
      Abstract: Background: This large-scale retrospective study was conducted to evaluate the effectiveness and safety of eribulin for the treatment of metastatic breast cancer in real-world settings in Korea.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.032
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 115PPathological complete response rates following neoadjuvant systemic
           therapy in 300 patients with early or locally advanced HER2 positive
           breast cancer: The Royal Marsden experience
    • Authors: Chaabouni N; Battisti N, True V, et al.
      Abstract: Background: Neoadjuvant chemotherapy plus anti-HER2 treatment is increasingly becoming the treatment of choice for all but the lowest risk HER2+ early and locally advanced breast cancer (BC). Patients achieving a pathological complete response (pCR) have substantially better outcomes compared with non-pCR. We evaluated the pCR rates following neoadjuvant systemic therapy in our HER2+ BC population and determined the influence of tumour and patient characteristics, and adverse events on pCR rates, disease free survival (DFS) and overall survival (OS).
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz097.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 68PFunctional CRISPR knockout screens for modifiers of sensitivity to
           trastuzumab emtansine
    • Authors: Lipert B; Siemens K, Khan A, et al.
      Abstract: Background: Therapies targeting HER2 amplification are a success of modern oncology, yet resistance to these agents remains a major challenge. For example, the mertansine- (DM1-) armed antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) extends the survival of HER2-positive metastatic breast cancer patients after failure of prior trastuzumab-based therapy. However, T-DM1 provides objective responses in less than half of patients and its effectiveness is limited by both acquired and intrinsic resistance.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.067
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 93OImpact of tamoxifen (TAM) serum concentration on side effects among
           premenopausal patients (pts) with early breast cancer (BC) in the
           prospective multicenter CANTO cohort
    • Authors: Ferreira A; Paci A, Meglio A, et al.
      Abstract: Background: TAM causes several side effects that impact the quality of life and adherence to treatment in patients with BC. Due to the complexity of TAM metabolism, serum biomarkers predicting TAM side effects have not been identified. We hypothesized that TAM levels may be associated with side effects, thus identifying pts eligible to tailored supportive interventions.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz096.007
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 46PBRCA mutations among triple negative breast cancer without family
           history of breast and ovarian cancer: The Modena family cancer clinic
           experience
    • Authors: Molinaro E; Venturelli M, Toss A, et al.
      Abstract: Background: Because of the high costs associated with genetic analyses, BRCA1/2-testing has traditionally been restricted to breast cancer patients having an ’a priori high risk’ of being a carrier. Particularly, according to The National Institute for Health and Care Excellence (NICE) in the UK, BRCA testing should be offered to breast cancer patients with a probability of having a mutation ≥ 10%. Regardless of family history, International Guidelines include among the BRCA testing Criteria, a personal history of triple negative breast cancer diagnosed ≤ 60 years. According to previous research, 15-30% of unselected TNBC had confirmed BRCA mutations. Whereas, among patients without breast/ovarian cancer family history mutation prevalence decrease to 6-15 %.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.045
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 137PCan sentinel node biopsy be considered in early breast cancer with
           axillary nodal disease'
    • Authors: May-Miller P; Zaidi M, Helme S, et al.
      Abstract: Background: Biopsy proven axillary disease in breast cancer is a contraindication for sentinel node biopsy and is considered a predictor of heavier nodal disease. This may not hold true for early breast cancer with clinically negative axilla with a positive ultrasound biopsy. Our study aimed to identify a group of such patients with minimal involvement of 1-2 lymph nodes, who may benefit from sentinel lymph node biopsy and avoid axillary clearance based on Z11 criteria.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz098.014
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 23PDesign of a protein signature predicting response to neo-adjuvant
           treatment with chemotherapy combined with bevacizumab in breast cancer
           patients
    • Authors: Haugen M; Lingjærde O, Garred Ø, et al.
      Abstract: Background: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer there is an unmet need to identify patients that benefit from such treatment.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.022
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 159P_PRInfluence on quality of life of chemotherapy scheduling for
           patients with advanced HER2-negative breast cancer
    • Authors: Claessens A; Timman R, Busschbach J, et al.
      Abstract: Background: The phase III Stop&Go study randomized patients with advanced breast cancer to two times four intermittent cycles or to eight continuous cycles of first- and second-line chemotherapy, yielding inferior overall survival (OS) with intermittent scheduling. Here we report on the prospectively planned quality of life (QoL) analyses.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz100.010
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
  • 2OPrognostic value of endopredict for invasive lobular carcinomas in the
           combined ABCSG-6/8 and TransATAC trials
    • Authors: Sestak I; Filipits M, Buus R, et al.
      Abstract: Background: Invasive lobular carcinoma (ILC) accounts for approximately 15% of all breast cancer cases. Most of the correlations between multigene assays and patient outcome were derived from studies based on mixed cohorts with IDC and ILC. Here, we specifically investigate the prognostic value of Endopredict (EPclin) in a large cohort of ILCs pooled from large phase III randomised trials.
      PubDate: Mon, 13 May 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz095.001
      Issue No: Vol. 30, No. Supplement_3 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 35.175.179.52
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-